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ABSTRACT
This thesis is a study of the causes and significance 
of local recurrence after breast-conserving surgery for 
breast cancer. Relevant published literature is 
reviewed. The core study involved 300 patients with
invasive breast cancer who underwent breast-conserving 
surgery. All patients had tumour bed analysis performed 
by pathological examination of a shaving taken from the 
cavity wall. This was excised after the surgeon had 
performed a wide macroscopic clearance of the tumour. 
Disease in the cavity shaving was found in 39.3% of 
cases (tumour bed positivity). Re-excision was 
performed selectively and all patients received post­
operative radiotherapy. At 4.4 years mean follow-up the 
local recurrence rate was 2.2% for breast-conserved 
patients and the systemic recurrence rate for all
patients was 10.4%. Tumour bed positivity was found to 
be significantly associated with higher tumour grade, 
presence of an extensive in-situ component, dense 
mammographic pattern, casting-type mammographic
calcification and absence of mammographic nidus. Non­
significant trends were observed between tumour bed 
positivity and smaller lumpectomy diameter, younger 
patient age and lobular carcinoma. Tumour bed
positivity was found to be significantly associated 
with poor distant disease-free survival. The 
implications of these findings are discussed.
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INTRODUCTION
Epidemiology of breast cancer
Globally, breast cancer is the most common cancer 
affecting women. It accounts for almost 20% of 
malignancies and over 500,000 new cases of breast 
cancer are registered every year^. In Scotland, between 
1981 and 1990, breast cancer accounted for 23.5% of all 
malignancies in women^. An average of 2633 new cases 
and 1257 deaths from the disease were registered each 
year and the 5 year relative survival rate was 64.3%. 
Over this 10 year period the incidence of breast cancer 
increased by 11.8%. A large part of this increase 
occurred between 1989 and 1990. Breast screening was 
introduced in a phased manner to Scotland from 1988 
with national coverage by 1991 and in 1993, 21% of all 
new cases of breast cancer were screen-detected^. 
Within the 50 to 64 age group screening has resulted in 
an increase in the proportion of cancers with a 
pathological tumour diameter of 2cm or less (36.7% in 
1987 and 59.4% in 1993).
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The history of surgery for breast cancer
The earliest documented case of attempted breast cancer 
surgery is found in the Edwin Smith papyrus that dates 
to 3000BC4. It is attributed to the Egyptian physician, 
Imhotep and recounts a variety of disease presentations 
and treatments. Eight cases of breast disorders are 
documented and case 39 describes treatment of a breast 
tumour with cauterisation using a fire drill. However, 
the earliest detailed description of surgical 
procedures used to treat breast cancer is derived from 
the works of Aetius, a Byzantine court physician of the 
6th century AD and Celsus, the author of De Medicina 
from Provence who lived in the 1st century AD. They 
documented the practices of many physicians and 
surgeons who were based in Alexandria after 300BC^. One 
such surgeon, Leonides, advocated excising breast 
tumours using a combination of cutting and cautery and 
it is believed that quite radical procedures were 
attempted at this time. The physician Galen (131AD - 
203AD) put forward theories on cancer aetiology based 
on humoralism. He advocated surgery only when the 
excision could be extended to healthy surrounding 
tissue, which was to be cauterised instead of ligated 
to burn the roots of the disease. He also recommended 
prescription of special diets and the application of
17
salves, caustics or ointments to ulcerated tumours, 
which were most likely to have been the mainstay of his 
practice^-^.
Interest in science and advancement of the theories put 
forward by this early civilisation were noticeable 
principally by their absence during much of the middle 
ages. The teachings of Galen remained the basis of 
breast cancer treatment during the thirteenth, 
fourteenth and fifteenth centuries. Italian Renaissance 
surgeons such as Bruno da Longoburgo and Guy de 
Chauliac advocated surgery only when the tumour was 
positioned such that wide excision was feasible, 
sometimes removing the entire breast^. The prevailing 
opinion was however that these procedures represented 
palliative treatment and success in curing a patient by 
surgery was rarely claimed.
The discovery of blood circulation by William Harvey in 
1628 and the later detailed description of lymph 
channels gradually altered the prevailing philosophy 
with regard to breast cancer aetiology and spread. 
Advances in anatomy and the development of 
sophisticated surgical tools, coupled with the 
introduction of formalised surgical training, led to a 
large increase in the number of surgeons practising 
breast cancer surgery during the seventeenth and 
eighteenth centuries. Enthusiasm was frustrated only by
18
the lack of anaesthesia, the frequent development of 
sepsis and short post-operative survival. Alexander 
Monro (1697-1767), professor of anatomy in Edinburgh 
reported that out of sixty cases of surgically treated 
breast cancer, only four remained alive without signs 
of disease after 2 years^. A wide variety of surgical 
procedures were employed at this time. Amputation of 
the breast was used for small tumours using a variety 
of surgical instruments specifically designed to 
expedite the procedure, which would usually last only a 
few minutes. William Cheselden (1688-1752) and Rene- 
Jacques Croissant De Gavengot (1689-1759) practised 
simple excision of the lump. Jean Louis Petit (1674- 
1750) who became the first surgical director of the 
French Academy of Surgery, described wide excision 
including pectoral fascia, en block resection and 
axillary dissection. Benjamin Bell (1749-1806) of the 
Royal Infirmary, Edinburgh recommended radical excision 
of the breast as soon as the diagnosis was made even if 
the tumour was small and in 1774 Bernhard Perilhe 
(1735-1804) advocated that radical excision include 
removal of pectoralis major^- .^ Surgery however, 
remained an unpopular treatment for breast cancer. The 
suffering endured by the patient during the procedure 
coupled with no observed survival advantage meant that 
surgery was invariably only sought at very advanced 
stages of the disease. In 1844 a large survey of
19
survivors beyond 2 years was carried out by Jean- 
Jacques-Joseph Leroy d'Etoiles (1789-1860) which 
concluded that operative treatment of breast cancer was 
more harmful than beneficial^.
During the early part of the nineteenth century
considerable advances were made in histology and cell 
biology eventually allowing diagnosis of cancer by 
microscopy. The introduction of surgical anaesthesia in 
1846 and antisepsis in 1867 revolutionised surgery in 
the mid 19th century. Antisepsis immediately halved the 
operative mortality to less than 10%. However, despite 
improved operating conditions, local control of disease 
was disappointing. In 1874, Sir James Paget reported a 
series of 235 patients who underwent surgery for breast 
cancer^. Operative mortality was 10% and all cases
recurred within 8 years. In 1867 the same year as
Joseph Lister reported on antisepsis, Charles Moore 
(1821-1870), surgeon to the Middlesex and St Lukes 
hospitals in London, published an important paper 
detailing the general principals on which he believed 
the surgical treatment of breast cancer should be 
based^. The paper was titled "On the influence of 
inadequate operations on the theory of cancer" and 
detailed the case histories of 14 patients who 
presented to the Middlesex hospital with locally
recurrent breast cancer at various times after surgery. 
From his observations Moore concluded that local
20
recurrence always occurred at the site of previous 
operation and that it was due to continuous growth of 
fragments of tumour remaining in the breast after the 
initial operation. He proceeded to recommend that the 
minimum operation for breast cancer should be complete 
mastectomy including wide skin clearance. In addition, 
he advocated extending the operation to encompass 
adjacent tissues if the tumour lay in close proximity 
to them and en-bloc removal of diseased axillary nodes 
without dividing the intervening lymphatics. Evidence 
that radical surgery might improve recurrence-free and 
overall survival was offered by Samuel Gross (1837 — 
1889), Professor of Surgery at Jefferson Medical 
College, who reported 200 cases of surgically treated 
breast cancerlO. No axillary dissection was performed 
in 55 patients and all died from recurrence shortly 
after surgery. Axillary dissection and removal of 
pectoral fascia was performed in the remaining patients 
and 3 year survival was 19.4%. The indication for 
radical surgery was also fuelled by the late 19th 
century anatomists who described microscopic tumour 
involvement of pectoral fascia and via lymphatics, 
pectoral muscle.
In 1882 William Halsted (1852-1922) whilst practising 
at the Roosevelt Hospital in New York, began to 
routinely remove pectoralis major en bloc with the 
breast and axillary nodes. In 1884 he published the
21
results of the first 50 cases treated this way and 
reported a local recurrence rate of 6% despite all 
patients being clinically node-positive at the time of 
surgeryll. This figure was ten times less than the 
local recurrence rates commonly reported at the time. 
Long follow-up showed that the local recurrence rate 
increased to 31.9%, which was still a considerable 
improvement on contemporary figures^. jn addition, his 
results for 232 operations were published in 1907 and a 
3 year survival rate of 38.3% was reported which was 
approximately double the observed rate in other series 
presented at the end of the 19th centuryl^. William 
Meyer described a similar operation to the Halsted 
mastectomy in 188414. included resection of
pectoralis minor in addition to pectoralis major, which 
Halsted later adopted. Halsted also performed a series 
of 119 operations that included supraclavicular node 
dissection. However, morbidity was high and only 2 of 
44 patients who were supraclavicular node-positive were 
alive after 5 years^. This modification of the 
operation was abandoned although future en bloc 
resections that included supraclavicular and internal 
mammary node dissections were envisaged. Such extended 
radical operations were performed on small series of 
patients during the early part of the 20th century but 
were abandoned due to high morbidity and no observed 
survival advantage over the standard procedure^. The
22
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1
L-
standard Halsted mastectomy involved wide skin 
excision, en bloc removal of both pectoral muscles, 
axillary dissection and Thiersh skin graft, and was 
widely adopted as the routine surgical operation for 
breast cancer.
The reported survival advantage conferred by radical 
mastectomy over less radical procedures has been 
contested^. Analyses of the published results of 
radical mastectomies performed during the early part of 
this century are fraught with difficulty. Formal 
staging of breast cancer was not a routine practice and 
details such as patient age and presence of nodal 
disease were frequently missing in reported series. In 
addition follow-up was often unavailable for over 20% 
of patients. An overview was performed by Lane-Claypon 
in 1924 who reviewed all literature prior to this 
date-*-^ . The early results of 20, 000 operations were 
analysed. Patients lost to follow-up or without 
histologically proven breast cancer were excluded. 
Following a non-radical mastectomy, the 3 year survival 
was 29.2% and following radical mastectomy, the 3 year 
survival was 43.2%. None of the patients included in 
this review were randomised to receive either treatment 
and the results are open to the criticism that 
selection bias played a large role in the survival 
differences observed. Nevertheless, the literature 
testifies to the popularity of radical mastectomy at
23
this time and it remained the standard operative 
procedure for breast cancer for three-quarters of a 
century.
The paradigm for breast cancer surgery put forward by 
Halsted was based on the theory that breast cancer 
spreads by direct extension into adjacent tissues. Even 
bone and liver metastases were explained by lymphatic 
spread of tumour with uninterrupted microscopic 
connections to the primary in the breast^. This theory 
was not contested until 1936 when anatomical studies of 
lymphatics demonstrated the lymphatic drainage of the 
breast and the presence of normal lymphatic channels 
between breast tumour and axillary metastases. The 
theory of cancer spread outwith the breast by 
embolisation was put forward-*-^ . In 1906 Handley 
described a modified radical mastectomy in which skin 
flaps were raised although most of the pectoral muscles 
were still excised^. He recommended this procedure for 
older patients or those with early cancers. In 1938 
Patey and Duson further modified this procedure and 
taking into account new scientific evidence relating to 
tumour spread, recommended preservation of pectoralis 
major except in advanced cases. Pectoralis minor was 
divided to allow a complete dissection of the axillary 
contents-*-^.
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Dissatisfaction with the morbidity caused by radical 
surgery, the tendency for patients to present earlier 
with less advanced tumours and the development of 
radiotherapy all contributed to a growing interest in 
more surgically conservative methods of breast cancer 
treatment. In 1937, Geoffrey Keynes presented the 
results of patients he had treated using interstitial 
radium with or without very limited surgery and
reported survival figures similar to those that would 
be expected from radical surgery!^. In 1948 Robert 
McWhirter suggested that if postoperative radiotherapy 
was used then radical surgery might be safely
substituted with simple mastectomy^O. The first 
randomised trial to show that equivalent degrees of
local control and survival could be achieved by these 
two methods of treatment was conducted between 1951 and 
1957 in Copenhagen^!. Other trialists randomised 
patients undergoing radical mastectomy to postoperative 
radiotherapy or no further treatment. The first such 
trial was conducted at the Christie Hospital in
Manchester between 1949 and 1955^2. At 10 years the 
incidence of local recurrence was reduced by 40% in the 
radiotherapy group. At 15 years however, a small 
survival benefit was observed for the non-irradiated 
group although this was shown to be due to the adverse 
cardiac effects of radiotherapy and not due to death 
from breast cancer. A recently published overview of
25
the eight trials started before 1975, which assessed 
the value of adjuvant radiotherapy after radical or 
total mastectomy, has reported that beyond 15 years 
follow-up there were a reduced number of deaths due to 
breast cancer in the group of patients who received 
radiotherapy^. This is set against an increased number 
of cardiac deaths in irradiated patients particularly 
influenced by the early trials.
During the 1950's and 1960's several investigators 
reported survival rates from series of patients treated 
by limited surgery and radiotherapy that were 
equivalent to those observed after radical s u r g e r y 2 4 ~  
27. These results, along with a growing understanding 
of the mechanisms of breast cancer spread and the 
introduction of high energy (super voltage) 
radiotherapy equipment in the late 1950's generated 
interest in conservative approaches to breast cancer 
surgery.
Breast-conserving surgery
The aim of breast-conserving surgery is to achieve 
maximal cosmesis with minimal physical and
26
psychological morbidity without compromising overall 
survival. One of its earliest exponents was Geoffrey 
Keynes who reported the results of a series of patients 
treated using radium wire implants to the breast and 
axilla followed by very limited surgery in 1937^-^. He 
found a 5 year survival of 71.4% in 85 Stage 1 patients 
and 29.3% in 92 Stage 2 patients. However, these 
promising results were slow to make any impact on 
surgical practice. Thirty years later, Peters et al 
reported a large group of patients 200 of whom were 
treated by excisional biopsy and 652 were treated by 
radical mastectomy26# Both groups received radiotherapy 
and 5 and 10 year survival results were identical. Wise 
et al reported the results of 96 patients treated by 
local excision and radiotherapy and found that survival 
in these patients was not significantly different to 
207 comparable patients treated by radical mastectomy 
with radiotherapy given to those who were node- 
p o s i t i v e ^ .  Local recurrence was observed in 9.4% of 
the patients treated by breast-conserving surgery. In a 
study by Taylor et al where sector mastectomy and 
radiotherapy was performed for 77 patients with tumours 
less than 5cm, the local recurrence rate was 18.2%2 .^ 
Local recurrence also occurred in 25.8% of patients 
treated with local excision and radiotherapy in a large 
retrospective review by Rissanen27. Despite this high 
local recurrence rate, survival at 5 and 10 years was
27
almost identical to a group of similar patients treated 
by radical mastectomy and radiotherapy.
The first randomised trial to assess breast-conserving 
surgery as an alternative to radical mastectomy was 
started by Sir Hedley Atkins at Guy’s hospital in 
1961^0. Over a 10 year period, 370 patients over age 50 
were randomised to either radical mastectomy or local 
excision of the tumour with a 3cm margin of normal 
tissue followed by radiotherapy. No axillary surgery 
was performed in the breast-conserving group. 
Radiotherapy after mastectomy consisted of 30Gy given 
to the supraclavicular and axillary fields over 3 
weeks. After local excision patients received this same 
treatment over 2 weeks with the addition of 30 Gy over 
2 weeks to the ipsilateral breast. Recurrence in the 
breast occurred in only 6 patients (3%) at 5 years. 
However, a higher incidence of regional recurrence was 
observed with a 15.4% axillary recurrence rate. 
Clinically node-positive patients in the breast- 
conserving group also had an increased rate of distant 
recurrence resulting in decreased overall survival 
compared to those treated by mastectomy. Patients who 
were clinically node-negative had equivalent distant 
disease-free and overall survival although more 
axillary recurrences were seen in the breast-conserving 
group who had no axillary surgery. The error in 
clinical node staging within the mastectomy group was
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found to be 25%. A second trial was conducted between 
1971 and 1975 which randomised 276 patients to the same 
treatment options but only included those who were 
clinically node-negative. This second trial reported
that regional recurrence, distant recurrence and 
survival were worse in the breast-conserving group and 
thus was in conflict with the results of the clinically 
node-negative subgroup in first trial^l. The overall 
results were confusing and did much to dissuade 
surgeons from practising breast-conserving surgery at 
this time.
The dose of radiotherapy used in the Guy's trials was 
by modern standards inadequate and a late analysis of 
the trial results suggested an explanation for the 
findings. A comparison of the two trials showed that 
the main difference between them was that patients who 
underwent radical mastectomy fared better in the second 
trial32. Analysis revealed that there was a 
significantly larger group of patients in the second 
trial with tumours less than 2cm in diameter. The
observed differences in the second trial between
radical and breast-conserving treatment were limited 
almost entirely to this group of patients. This 
analysis suggested that radical surgery may confer a
survival benefit for patients with early (localised) 
disease and inferred that inadequate local treatment 
especially to the axilla, may adversely affect outcome.
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The trial also demonstrated that a low local recurrence 
rate can be achieved with a wide, 3cm clearance around 
the tumour. Only 6 local recurrences occurred in the 
breast-conserving group in the second trial at 5 years 
(5%) .
To-date seven randomised trials have compared 
mastectomy with breast-conserving surgery plus 
radiotherapy. One trial failed due to the constraints 
of informed consent resulting in poor patient 
a c c r u a l ^ .  Six trials have published medium to long­
term r e s u l t s - 3 4 - 3 9 . The protocols of these trials varied 
slightly and are summarised in Table 1. With follow-up 
ranging from 6 to 13 years these trials have 
demonstrated no significant difference in overall 
survival, and distant disease-free survival between the 
various treatment arms [Table 2].
The use of breast-conserving surgery sharply increased 
during the late 1980's as the early results of these 
trials were declared. In a survey of 16 radiotherapy 
departments in the Netherlands, the number of patients 
treated by breast-conserving surgery more than doubled 
between 1986 and 1990^0. By 1990, 36% of all women with 
newly diagnosed invasive breast cancer were treated in 
this way. In Scotland the use of breast-conserving 
surgery increased from 40% of cases in 1987 to 52% in 
1993^. The encouraging results of randomised trials
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comparing breast-conserving surgery and radiotherapy 
with mastectomy prompted the design of trials assessing 
the need for post-operative radiotherapy. A course of 
radiotherapy after breast-conserving surgery usually 
involves 40 to 50 Gy given in 20 to 25 daily fractions 
over 5 or 6 weeks with a boost of 10 to 20 Gy over 7 or 
14 days to the site of excision. Apart from the 
inconvenience of such a treatment schedule, 
radiotherapy may be associated with significant 
physical and psychological side effects such as 
fatigue, skin irritation, telangectasia, breast 
fibrosis, respiratory symptoms, mild dysphagia, 
anorexia and anxiety^ -*-' 42 # Five randomised trials have 
therefore, compared breast-conserving surgery alone 
with breast-conserving surgery plus adjuvant 
radiotherapy^, 43-46. protocols are summarised in
Table 3. With follow-up ranging from 4-9 years no 
significant difference in overall survival or distant 
disease-free survival between the various treatment 
arms has been reported although small non-significant 
differences have been observed. However, highly 
significant differences in the incidence of local 
recurrence were found in all these trials with 
unacceptably high rates for non-irradiated 
patients[Table 4].
Local recurrence after breast-conserving surgery is a 
significant concern. It potentially undermines all the
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aims of breast-conserving surgery. Psychologically, a 
patient will lose confidence in her treatment, suffer 
the anxiety of cancer recurrence and may face the 
prospect of undergoing a mastectomy. The cosmetic 
benefits of breast-conserving surgery are therefore 
lost. In addition, there is also the theoretical 
concern that in certain patients, inadequate local 
treatment may allow disease dissemination and adversely 
affect outcome. When patients with local recurrence are 
analysed separately, associations between local 
recurrence and shorter distant disease-free and overall 
survival have been reported^, 47-49. -phe significance 
of this association is the subject of considerable 
debate.
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Table 1. Randomised trials of breast-conserving
surgery plus radiotherapy versus mastectomy
(Protocols).
TRIAL NUMBER OF 
PATIENTS
TUMOUR
SIZE
RADIOTHERAPY
MILAN I
(1973-1980)
701 <2 cm 50Gy (plus lOGy 
boost)
NSABP B-06
(1976-1984)
1843 <4 cm 50 Gy (no boost)
WHO
(1972-1980)
179 <2 cm 45Gy (plus 15Gy 
boost)
NCI
(1979-1987)
237 <5 cm 48Gy (plus 15- 
20Gy boost)
EORTC
(1980-1986)
878 <5 cm 50Gy (plus 25Gy 
boost)
DANISH
(1983-1989)
859 Not
defined
50Gy (plus 20Gy 
boost if margin 
positive)
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Table 2. Randomised trials of breast-conserving
surgery plus radiotherapy versus mastectomy (Results).
TRIAL RANDOMISATION FOLLOW
-UP
OS DDFS
MILAN I Quadrantectomy + 
Radiotherapy 
V
Mastectomy
13
years
71%
V
69%
NSSD
NSABP B-06 Lumpectomy + Radiotherapy 
V
Mastectomy
9
years
69%
V
68%
60%
V
63%
WHO Lumpectomy + Radiotherapy 
V
Mastectomy
10
years
79%
V
80%
NSSD
NCI Lumpectomy + Radiotherapy 
V
Mastectomy
10
years
77%
V
75%
NSSD
EORTC Lumpectomy + Radiotherapy 
V
Mastectomy
8
years NSSD NSSD
DANISH Lumpectomy + Radiotherapy 
V
Mastectomy
6
years
79%
V
82%
NSSD
OS = Overall Survival, DDFS = Distant Disease-Free 
Survival, NSSD = No statistically significant 
difference (actual values not available)
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Table 3. Randomised trials of breast-conserving
surgery plus or minus radiotherapy (Protocols).
TRIAL NUMBER
OF
PATIENTS
TUMOUR
SIZE
REQUIRED
MARGIN
RADIOTHERAPY
MILAN III
(1987-1989)
567 <2.5cm 2-3cm gross 50Gy (plus 
lOGy boost)
NSABP B-06
(1976-1984)
1843 <4 cm 1cm gross + 
pathologically 
clear
50Gy (no 
boost)
OCTRF
(1984-1989)
837 <4 cm Gross + 
pathologically 
clear
40Gy (plus 
12.5Gy 
boost)
SWEDISH
(1981-1988)
381 <2 cm 2 cm
pathological
clearance
54Gy (no 
boost)
SCOTTISH
(1985-1989)
585 <4 cm 1cm Gross 50Gy (plus 
10-15Gy 
boost)
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Table 4. Randomised trials of breast-conserving
surgery plus or minus radiotherapy (Results).
TRIAL RANDOMISATION FOLLOW
-UP
OS DDFS LRR
MILAN III Quadrantectomy
V
Quadrantectomy + 
Radiotherapy
4
years
NSSD NSSD
8.8%
V
0.3%*
NSABP B-06 Lumpectomy
V
Lumpectomy + 
Radiotherapy
9
years
68%
V
69%
59%
V
60%
43%
V
12%*
OCTRF Lumpectomy
V
Lumpectomy + 
Radiotherapy
7.6
years
76%
V
79%
N/A
35%
V
11%*
SWEDISH Sector resection 
V
Sector resection + 
Radiotherapy
5
years
90%
V
91%
87.1%
V
90%
18.4%
V
2.3%*
SCOTTISH Lumpectomy
V
Lumpectomy + 
Radiotherapy
6
years
81. 6% 
V
83.2%
64%
V
79.8%
24.5%
V
5.8%*
OS = Overall Survival, DDFS = Distant Disease-Free 
Survival, LRR = Local Recurrence Rate, * =
Statistically significant, NSSD = No statistically 
significant difference (actual values not available), 
N/A = Not available
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Local recurrence after breast-conserving surgery
The mechanism of local recurrence
Local recurrence after breast-conserving surgery is 
defined as disease recurring in the ipsilateral breast. 
It may arise either due to residual disease left in the 
breast at the time of surgery for the primary tumour or 
alternatively due to a second primary tumour developing 
in the breast. Throughout the evolution of surgery for 
breast cancer the possibility of leaving behind 
residual disease has been a cause for concern. All 
trials of breast-conserving surgery have therefore 
adopted measures to ensure complete local excision of 
the tumour. This practice was supported by laboratory- 
based studies involving serial sectioning or simulated 
wide local excision of tumours in mastectomy specimens. 
Several such studies have been p e r f o r m e d ^ O ' ^ l # The 
incidence of multicentricity in these studies varied 
according to the detail with which the specimens were 
examined. When 1 or 2 random samples from each quadrant 
were analysed, multicentricity was found in 18% of 
cases^. Rosen et al performed quadrantectomy or wide 
local excision with a 2 cm margin in 203 mastectomy 
s p e c i m e n s ^ .  Only 2 or 3 sections were taken from each
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remaining quadrant. Residual microscopic invasive or 
in-situ disease was found in 26% of specimens 
containing tumours less than 2 cm in diameter and 38% 
of those containing tumours larger than 2 cm. Egan 
developed a standardised method of pathological- 
radiological whole organ analysis. Multicentricity was 
found in 69% of 161 specimens when 5mm sections of the 
whole breast were taken^. An important study by 
Holland et al analysed 282 mastectomy specimens by 
serial sectioning in a similar way to Egan^. All of 
these patients had invasive breast cancer and were 
theoretically suitable for breast-conserving surgery 
with no clinical or mammographic evidence of multifocal 
disease, no skin or chest wall fixation and 
histological tumour diameter less than 5cm. Specimens 
were sectioned at 5mm intervals and the presence of 
microscopic disease was recorded and mapped on a 
topogram. Tumour foci were found in 43% of specimens 
(27% non-invasive and 16% invasive) outside a radial 
distance of 2cm from the reference tumour. This would 
represent residual disease had the patients undergone 
breast-conserving surgery with a 2cm gross clearance 
margin. An important finding was that the distribution 
of tumour foci was independent of tumour size. For 
tumours less than 2cm diameter residual invasive or in- 
situ disease was found in 59% of specimens at a 
distance of 1cm, 42% at a distance of 2 cms, 17% at a
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distance of 3 cms and 10% at a distance of 4 cms from 
the macroscopic edge of the tumour. A recent study 
using similar methods of analysis in 30 mastectomy 
specimens has corroborated these f i n d i n g s ^ ! .  These 
results have accurately predicted the incidence of 
local recurrence observed in clinical trials where 
radiotherapy was not administered. In the lumpectomy 
only arm of the NSABP-B06 trial where a 1cm clearance 
margin was taken around the tumour, the local 
recurrence rate was 27.9% at 5 years and 53% at 10 
years^2,63e jn the quadrantectomy only arm of the Milan 
III trial where a 2-3cm clearance might be expected, 
the local recurrence rate was 8.8% at 3 years^. 
Invasive residual disease might be expected to be 
responsible for early local recurrence whilst residual 
in-situ disease might declare as a later recurrence. 
Another interesting finding in Holland's study was that 
41% of patients had no evidence of tumour outwith the 
macroscopic tumour mass suggesting that surgical 
excision alone may be adequate local treatment for a 
significant minority of patients.
There is strong support for the view that the large 
majority of local recurrences represent residual 
disease. In an early analysis of the lumpectomy 
patients in the NSABP-BO 6 trial, all 110 local 
recurrences occurred in or close to the quadrant of the 
original tumour. The histological types and grades were
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identical in 86%64. In an overview of patients treated 
by quadrantectomy in Milan, 60% of local recurrences 
were of the same histological type and 79% occurred at 
or very close to the site of previous excision^. Kurtz 
et al reported that 86% of local recurrences that 
occurred within 5 years affected the site of previous 
wide local excision^. Only 75% of local recurrences 
that occurred between 5 and 10 years and 36% of those 
presenting after 10 years affected the site of previous 
excision. In a study of 990 patients treated by 
lumpectomy with a median follow-up of over 5 years, 
Haffty et al analysed local recurrences in terms of 
location, histology and DNA flow cytometry^, of 80 
recurrences, 59% were classified as representing 
residual disease and 41% as new primary tumours. The 
time to local recurrence was significantly shorter in 
those patients with local recurrence secondary to 
residual disease (3.6 years) compared with those 
thought to have a second primary cancer (5.7 years). In 
the NSABP-B06 trial, the annual rate of local 
recurrence in the lumpectomy only arm decreased from 
8.5% during the first 3 years follow-up to 4.6% in 
years 4 to 9, whereas in the lumpectomy plus 
radiotherapy arm the rate of local recurrence was 
constant at 1.4%49. Thus the evidence strongly favours 
attributing early local recurrence to residual disease. 
The cause of late local recurrence or recurrence in the
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breast distant from the site of previous excision is 
less clear.
It is difficult to distinguish between local recurrence 
due to residual disease from that due to a new primary 
tumour. Previous studies have highlighted the degree to 
which many breast tumours are multicentric^^-^^. In the 
Milan II trial which compared quadrantectomy plus 
radiotherapy (QUART) with tumourectomy plus 
radiotherapy (TART) local recurrence was defined as 
tumour relapse within 3cm of the surgical 
scar^' ^ .Recurrence in the breast beyond this was 
defined as a new primary. Significant differences were 
observed in the incidence of local recurrence, 
confirming that a wider excision margin reduces the 
risk, but there was no significant difference in the 
incidence of new primaries. In addition, the incidence 
of contralateral tumours was similar for both QUART and 
TART groups and was greater than the incidence of new 
primaries in the ipsilateral breast. Thus the incidence 
of new primaries was no greater than expected. It may 
even be less, suggesting that radiotherapy may protect 
the breast from developing a second primary breast 
cancer.
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Assessing margins of excision
Various methods of assessing completeness of excision 
have been devised. Patients with evidence of incomplete 
excision can be selected for subsequent wider excision 
or mastectomy. In the NSABP-B06 trial, margins were 
assessed using the technique of India Ink s t a i n i n g ^ .  
This involved coating the lumpectomy specimen in ink 
and taking sections from the anterior, posterior, 
medial and lateral aspects of its inked surface. These 
were blocked sagitally and excision was deemed 
incomplete only when tumour had been transected by the 
inked margin. In this trial, between 12 and 20 blocks 
were taken from each specimen. In all, 10% of patients 
were shown to have involved margins and subsequently 
underwent mastectomy. Only 29% of mastectomy specimens 
contained residual disease. However, a review of the 
histological slides of patients thought to have margin 
involvement, demonstrated a lack of consensus agreement 
among different pathologists in 69% of cases. Where 
agreement was reached, residual disease was found in 
67% of mastectomy s p e c i m e n s ^ .  Despite this policy, 
local recurrence rates in this trial were high. This 
method of margin assessment appears therefore, to 
markedly underestimate the true incidence of residual 
disease after lumpectomy. Frazier et al used the same
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criteria as the NSABP-B06 trial to assess m a r g i n s ^ .  in 
this study of 87 patients who underwent diagnostic 
excision biopsy for breast cancer, 75 patients 
subsequently opted for mastectomy regardless of margin 
status and 12 patients who wished breast conservation 
had a re-excision performed for involved margins. 
Original margin status and incidence of residual 
disease in the breast could therefore be compared. Re­
excision and mastectomy specimens contained residual 
tumour in 52% of those with involved margins, 32% of 
those with uninvolved but close margins and 26% of 
those with clear margins. Close margins have been 
variably defined as tumour found within 1, 2 or 5mm
from the inked surface^-^ . Gwin et al demonstrated 
residual disease in 65% of patients with a positive 
margin, 23% with a close margin and 45% where the 
margin status was u n k n o w n " ^ .  Five year local recurrence 
rates have been reported as being between 2 and 21% for 
patients with positive margins and between 4 and 11% 
for those with close margins^' 71. jn two studies no 
local recurrences have been recorded at 5 years for 
patients with negative margins after initial surgery or 
re-excision^^'71. However, in one of these studies over 
50% of patients had positive margins initially and 
therefore required re-excision^. In a prospective 
study of 87 patients only those with a pathologically 
clear margin of at least 1cm as determined by inking,
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were included^. No radiotherapy was administered and 
local recurrence occurred in 16% of patients by 4.5 
years. A total of 78% of recurrences affected the 
original tumour site. The technique of analysing 
margins by inking has been criticised previously. It 
has been stated that sections taken from the surface of 
an irregular, fatty lumpectomy specimen are likely to 
assess the least pathologic areas of the specimen”^ .  
Even if sectioning is targeted to apparent stellate 
extensions of the tumour which are in any case 
difficult to detect three-dimensionally, areas of in- 
situ disease will be missed. An almost infinite number 
of sections would be required to accurately detect 
disease on the surface of a lumpectomy specimen.
Other methods of assessing the margin of excision 
include taking multiple biopsies from the cavity 
remaining in the breast following lumpectomy. Umpleby 
et al demonstrated that after taking biopsies from the 
superior, inferior, medial, lateral and deep margins of 
the cavity wall, residual disease was found in 25% of 
p a t i e n t s ^ .  Frozen section is of little value due to 
the number of sections required for margin assessment 
and the difficulty in diagnosing in-situ disease by 
this method^. in summary, analysis of resection 
margins can indicate that incomplete excision is 
likely. However, assessing completeness of excision is 
difficult, labour intensive, and current methods appear
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flawed. It is therefore important to also establish the 
other factors that might accurately predict patients at 
risk of developing local recurrence.
Risk factors for local recurrence after breast- 
conserving’ surgery
Extensive intraduct component
The presence of an extensive intraduct component (EIC) 
within the tumour was proposed as a risk factor for 
local recurrence by the Joint Centre for Radiation 
Therapy (JCRT) . EIC is defined as being present if an 
infiltrating ductal carcinoma has both prominent 
intraduct carcinoma present within the tumour (also 
specified as >25%) and intraduct carcinoma present in 
sections of grossly normal adjacent breast tissue. 
Tumours which are predominantly intraductal with foci 
of invasion are also considered to have EIC. Vicini et 
al demonstrated that in 584 patients treated by local 
excision and radiotherapy, 5 year local recurrence 
rates were 21% in 166 patients who had EIC and only 6% 
in 418 patients without EIC. Patients with EIC
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accounted for 58% of all local recurrences. Almost all 
recurrences occurred at the operation site^'^. jn an 
analysis of the series of mastectomy specimens 
previously reported to show residual disease at varying 
distances from the macroscopic edge of the tumour, 
Holland et al looked specifically at the influence of 
EIC on their o b s e r v a t i o n s ^ ,  79  ^ g g  specimens where
the tumour exhibited EIC, the incidence of residual 
disease was significantly greater (74%) when compared 
with 151 specimens that did not show EIC (42%) . Further 
analysis showed that this difference was predominantly 
due to a greater incidence of residual intraduct 
carcinoma in patients with EIC. In addition, 44% of 
patients with EIC had prominent residual intraduct 
carcinoma (greater than five low power fields) compared 
to 3% of patients without EIC. A detailed study using 
computer graphic three-dimensional mapping of mammary 
duct systems has shown that the degree and distance of 
intraduct tumour extension is greater for tumours with 
EIC^O. EIC has no effect on the incidence of recurrent 
tumour within the breast distant from the site of 
previous excision^lr 82#
The significance of EIC in relation to the incidence of 
local recurrence has been analysed in some of the 
randomised trials of breast-conserving surgery. EIC was 
found to be a highly significant predictor for local 
recurrence in the Milan II trial particularly for
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patients in the tumourectomy group where local 
recurrence was seen in 28% of patients who had EIC^. 
EIC accounted for 18% of all local recurrences in an 
overview of patients treated by q u a d r a n t e c t o m y ^ 7 . No 
association between local recurrence and EIC was found 
in the NSABP B-06 trial and this is the major exception 
to the consensus that EIC is an important predictor of 
local r e c u r r e n c e ^ .  An important difference between 
these trials was the fact that 10% of patients in the 
NSABP-B06 trial had a mastectomy because of positive 
resection margins but were analysed in their original 
randomised treatment arm. In addition, the reported 
incidence of tumours with EIC varied. It was reported 
as being present in 13% of patients in the NSABP-B06 
trial but only 6.7% of those in the Milan trials^, 83^ 
In the JCRT study EIC was present in 28% of patients 
and in the pathological study by Holland et al EIC was 
present in 30% of s p e c i m e n s 7 ^ , 79# Thus definition and 
interpretation of what constitutes EIC appears to vary 
considerably between different institutions.
The type of intraduct carcinoma present may be 
important. Lindlay et al found that comedo-type 
intraduct carcinoma was associated with a local 
recurrence rate of 50%84# This is in accordance with 
studies of pure ductal carcinoma in situ (DCIS). In the 
NSABP-B17 trial of breast-conserving surgery for DCIS, 
comedo necrosis and involved margins were the only
47
independent predictors of local recurrence^. Schwartz 
et al observed that of 70 patients who had wide 
excision of DCIS, there were 11 recurrences at 4 years. 
All but one had comedo DCIS as the primary lesion86. In 
addition the presence of EIC can frequently be 
predicted by identifying typical patterns of
microcalifications on pre-operative mammograms8 .^
Lymphatic/vascular invasion
Lymphatic and vascular invasion may be identified 
separately but are often considered together as 
"vascular" invasion. Vascular invasion is defined as
the presence of tumour emboli within an endothelium- 
lined vascular space. In one large series, this was 
identified in 23% of breast tumours88. Lymphatic 
invasion was found to significantly predict for local 
recurrence in the Milan overview of quadrantectomy
patients^. It was only found in 6.5% of patients but
24% of all local recurrences occurred in this group. In 
the NSABP-B06 trial, lymphatic invasion was associated 
with a significantly increased risk of local recurrence 
in patients undergoing breast-conserving surgery. This 
association was noted at 3 years follow-up but lost 
statistical significance with longer f o l l o w - u p 6^ r 64  ^ jn
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an analysis of 518 patients treated at the Institute 
Curie, 6% of patients had vascular invasion and 13% of 
all local recurrences occurred in this group^. Locker 
et al found vascular invasion in 24% of tumours, which 
strongly correlated with local recurrence^. Vascular 
invasion was the most powerful predictor for local 
recurrence in this series of patients.
Histological type and grade
Other pathological factors reported to be significant 
predictors for local recurrence include histological 
type and histological grade of the tumour. It was 
initially thought that lobular carcinoma would not be 
suitable for breast-conserving surgery due to its 
association with multicentricity. Studies have shown 
however, that local recurrence rates comparable with 
those for ductal carcinoma can be achieved^-*-' ^ 2 ^ 
Lobular carcinoma was not associated with an increased 
risk of local recurrence in the Milan or NSABP 
conservation t r i a l s ^ ,  62 ^ The importance of 
histological grade varies between studies and with the 
type of grading system used. The NSABP-B06 trial 
reported that nuclear grade was a significant predictor 
for time to local recurrence in node positive patients
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after long follow up^2. Where the Bloom and 
R i c h a r d s o n ^  classification of tumour grade has been 
adopted the risk of local recurrence has generally been 
found to increase with increasing graded, 90, 94
Tumour size
Tumour size has been reported to be a predictor for 
local recurrence in many studies. Local recurrence was 
significantly more common in patients with pathological 
tumour size greater than 2cm compared with smaller 
tumours in the NSABP-B06, EORTC and Milan trials 
particularly in those patients who did not receive 
r a d i o t h e r a p y - ^ '47,49,62  ^ other investigators have found 
the same observations in non-randomised s t u d i e s ^ .  Some 
studies have also found difficulty in obtaining 
pathologically clear margins of resection in patients 
with large tumours^'^2. Interestingly, the incidence 
of widespread microscopic disease around the tumour was 
not related to tumour size in Holland's series of 
sectioned mastectomy specimens, although Rosen et al 
demonstrated that large tumour size was associated with 
multifocal d i s e a s e ^ ' 57  ^ jn a study by Vaidya et al, 
which used similar methods of analysis to Holland et 
al, multicentricity was related to tumour size^l.
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However, although larger tumours were more likely to 
have surrounding multicentric foci, they were not any 
more extensive or likely to be any further removed from 
the macroscopic edge of the tumour. The probability 
that these foci would be excised with a 1 or 2cm 
clearance margin around the tumour was not therefore 
related to tumour size. It is likely that wide local 
excision of large tumours is at times technically 
difficult and that tumour size assumes importance when 
surgical clearance is limited for cosmetic reasons.
Age
A consistent association between young age and 
increased risk of local recurrence has been reported. 
Patients younger than 35 years appear to be at 
particularly high risk. In the Milan overview of 
quadrantectomy patients, young women were significantly 
more likely to develop local recurrence in Cox 
regression analysis^. Women over age 70 were very 
unlikely to develop local recurrence. However, 
associations have also been reported between young age 
and multicentricity, multifocality, vascular invasion, 
high tumour grade and Eic95~98# young age may not be
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independently significant when these factors are taken
into account.
The presence of EIC, lymphatic invasion, poor 
histologic grade, large tumour size and young age have 
therefore all been implicated with increased risk of 
local recurrence. Locker et al have reported a series 
of 253 patients treated by breast-conserving surgery 
and radiotherapy where the local recurrence rate was 
21%. They found that the risk of local recurrence could 
be estimated using a prognostic index calculated from a 
combination of weighted values attached to tumour 
stage, tumour size, patient age and the presence of 
vascular invasion99.
The significance of local recurrence after breast- 
conserving surgery
It has been argued that local recurrence is of no 
significance and that attention given to it in the 
literature is exaggerated99' 100. This opinion is based 
on the fact that in the most recent trials, local 
recurrence rates are low. This has been attributed to 
the more widespread use of chemo-endocrine therapy,
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which as might have been expected, reduces the 
incidence of local recurrence^' 38, 47, 62, 101, 102 # 
results of the breast conserving trials [Table 2 &
Table 4] show that overall survival and the risk of 
developing distant recurrence following surgery for 
breast cancer has no statistically significant 
association with either the extent of the surgical 
procedure or the administration of post-operative 
radiotherapy. However, when patients who develop local 
recurrence are analysed separately and compared to 
those without local recurrence, a clear difference in 
distant disease-free and overall survival is observed.
In the NSABP B-06 study, a Cox regression model 
analysis of local recurrence demonstrated that patients 
who developed local recurrence were 3.41 times more 
likely to develop distant d i s e a s e ^ .  in addition, at 1, 
2 or 5 year cut-offs patients who had early local 
relapse were significantly more likely to develop 
distant disease than those who experienced this event 
late. A similar analysis was performed on results from 
the OCTRF randomised trial of breast-conserving surgery 
with or without radiotherapy^. This showed that the 
relative risk of both distant disease and overall 
mortality were more than doubled in patients who had 
local recurrence (2.11 and 2.18 respectively). Again, 
patients who developed local recurrence within one year 
were at significantly higher risk than those in whom
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local recurrence occurred late. Applied to data from 
the Milan breast-conservation trials and a large group 
of non-randomised patients treated by quadrantectomy 
the Cox regression model analysis has shown the risk 
for distant disease to be 4.62 times greater in 
patients who had a local recurrence. In this trial the 
risk was six times greater if local recurrence occurred 
within 1 year^7. It has been shown by Kurtz et al that 
survival relative to the onset of local recurrence 
varied significantly in a non-randomised study of 1593 
patients treated by breast-conserving surgery and 
radiotherapy with follow-up of 11 years. Patients who 
developed local recurrence after 5 years had the same 
overall survival as those who were d i s e a s e - f r e e ^ .  jn 
the group of patients who had local recurrences 
analysed in terms of location, histology and DNA flow 
cytometry by Haffty et al, the 5 year survival rate 
following breast recurrence varied from 89% in those 
with second primaries to 36% in those with recurrences 
due to residual disease^. Early local recurrence 
appears therefore to be strongly associated with the 
development of distant disease.
Some risk factors for local recurrence are risk factors 
for both local recurrence and distant disease and some 
are not. In addition, not all patients who get local 
recurrence are at increased risk of distant disease. 
EIC, whilst strongly predicting residual disease and
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local recurrence does not as might have been predicted 
correlate with distant disease-free or overall 
s u r v i v a l ^ ® , 81,82# Lymphatic/vascular vessel invasion 
and tumour grade however correlate with local 
recurrence, distant disease and overall s u r v i v a l ^ , 88, 
89,90,104,105.
The evidence implicating local recurrence with the 
development of disseminated disease does not however, 
translate into significant differences in distant 
disease-free or overall survival between the treatment 
arms of randomised trials. This is surprising
considering the large differences in the incidence of 
local recurrence observed. In the NSABP B-06 trial the 
cumulative incidence of local recurrence at 10 years 
was 53% in the lumpectomy only group compared with 12% 
in the group which received adjuvant radiotherapy. 
However, there was no significant difference in the 
incidence of distant disease or overall survival
between these g r o u p s ^ 2 .  Four other trials of breast- 
conserving surgery plus or minus radiotherapy have 
supported this finding although non-significant 
differences in distant disease-free survival have been 
reported in favour of patients who received
radiotherapy [Table 4]. Preventing local recurrence in 
the breast by performing a mastectomy has not been 
shown to lower the incidence of distant disease or 
improve survival [Table 2],
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Arguments have been postulated to explain this apparent 
inconsistency. Firstly, if local recurrence did cause 
distant disease, predicted differences in outcome would 
be small and the numbers of patients and duration of 
follow-up in each of these trials may not be sufficient 
to detect this. This argument is supported by the long­
term results of patients undergoing adjuvant 
radiotherapy following mastectomy in which a survival 
benefit conferred by radiotherapy was only seen after 
15 years23. Similarly an apparent benefit of radical 
surgery for small tumours was seen in the Guy’s trials 
after 15 years^. it has also been suggested that local 
recurrence after breast-conserving surgery is a marker 
for distant disease rather than the cause for it^9. A 
patient's risk of developing distant disease would thus 
be pre-determined before treatment, with local 
recurrence being a manifestation of this risk.
If local recurrence was to influence survival or the 
incidence of distant disease directly, then it might be 
expected that such an effect would be more apparent in 
patients who were node-negative at the time of initial 
surgery. Such patients would be more likely to have 
localised disease and would be less likely to receive 
adjuvant systemic therapy. In the NSABP-B06 trial all 
patients who were node-positive received
chemotherapy^. jn a recently available re-analysis of 
the trial, excluding patients from a single clinic
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where fraudulent data submission was identified, 
follow-up is continued beyond 10 years^-^. A 12% 
difference in distant disease-free survival was 
observed between node-negative patients in the 
lumpectomy only and the irradiated group (58% and 7 0% 
respectively). In addition, overall survival among 
node-negative patients varied by 4% (74% and 78%
respectively). The differences in distant disease-free 
and overall survival were increased from the 5 year 
follow-up figures (8% and 2% respectively) . For all 
patients in this re-analysis of the NSABP-B06 trial, 
distant disease-free and overall survival at 10 years 
was 61% and 66% for the mastectomy group, 62% and 71% 
for the lumpectomy plus radiotherapy group and 55% and 
65% for the lumpectomy only group respectively. A study 
using Bayesian analysis of the NSABP-B06 data estimated 
the probability that radiotherapy conferred a positive 
benefit to patients who were lymph node and margin 
negatively. The probability was 65% at 5 years 
increasing to 87% at 10 years with a relative reduction 
in annual mortality of 8.2% and 17.5% respectively.
Distant disease-free survival differed by 16% in favour 
of irradiated patients in the Scottish trial^G. The 
local recurrence rates for irradiated and non­
irradiated patients were 5.8% and 24.5% respectively. 
In this trial all oestrogen receptor positive patients 
received tamoxifen and all oestrogen receptor negative
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patients received chemotherapy. Thus, systemic therapy 
cannot substitute for radiotherapy to achieve local 
disease control. However the effect of systemic therapy 
on local recurrence has been widely reported and may be 
pronounced in the first few years of follow-up. The 
results of adjuvant tamoxifen and polychemotherapy 
trials show that the benefit for disease-free survival 
was two or three fold greater than the benefit for 
overall survival at 5 years f o l l o w - u p ^ - ^ 2 ,  107 # This was 
predominantly due to a decreased incidence of local and 
regional recurrences in patients receiving systemic 
therapy and most of these were local recurrences. At 10 
years however, the benefit for disease-free and overall 
survival was identical. An explanation for this effect 
is that adjuvant chemo-endocrine therapy has a 
preferential effect on soft tissue, as opposed to bony 
metastases.
In summary, there is no hard evidence to support the 
theory that local recurrence may directly effect 
patient outcome by disease dissemination. There is 
however, considerable indirect evidence to suggest that 
local control may be critical for patients with early 
breast cancer for whom local therapy is potentially 
curative.
To achieve the aims of breast-conserving surgery, local 
recurrence must be avoided and survival must be no
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worse than that after more radical surgery. In order to 
minimise local treatment for breast cancer without 
compromising safety, a better insight into the causes 
of local recurrence is required, with better criteria 
for patient selection. The aim of this thesis is to 
further the current understanding of these specific 
areas.
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CHAPTER 1
INTRODUCTION
Incomplete surgical excision of the primary tumour is 
the primary cause of local recurrence after breast- 
conserving surgery for breast cancer as outlined 
earlier. The exact incidence of incomplete excision is 
unknown. However in the study by Holland et al in which 
mastectomy specimens from patients who would have been 
theoretically suitable for breast-conserving surgery 
were serially sectioned, residual disease was predicted 
in 42-59% of patients depending on the macroscopic 
clearance margin^. a local recurrence rate within this 
range has been reported for patients not receiving 
radiotherapy in a randomised t r i a l ^ 2 .
The completeness of surgical excision, both macoscopic 
and microscopic is difficult to determine due to a 
combination of factors. In most cases the tumour edge 
is not uniform or rounded. Eccentric intraductal 
extension of tumour is common^. The lumpectomy 
specimen also has an irregular edge with a large 
surface area. Identifying microscopic disease at the 
surface of this specimen would require an impractical 
number of tangential s e c t i o n s ' ^ .  The technique of using
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India ink staining to assess resection margins is 
cumbersome and time-consuming. It typically reports 
margin involvement in approximately 10% of patients of 
which only half or less than half may have evidence of 
residual disease in a further resection s p e c i m e n ^ /68. 
In addition, the definition of margin positivity may be 
somewhat subjective^. Local recurrence rates after 
breast-conserving surgery have not been convincingly 
reduced in trials using this method of margin 
assessment^' 44, 45 ^
A previous study has described the technique of taking 
biopsies from the cavity wall remaining in the breast 
following breast-conserving surgery. In a study of 51 
patients where 5 such biopsies were taken in each case, 
the incidence of residual disease detected was 2 5 %^.
This study presented in this chapter was designed to 
answer the following questions:
• Is shaving the lumpectomy cavity a practical method 
for assessing completeness of excision during 
breast-conserving surgery for breast cancer?
• What is the incidence of residual disease after 
breast-conserving surgery for breast cancer?
• What are the clinical and pathological risk factors 
associated with residual disease?
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PATIENTS AND METHODS
Patients
Three hundred patients entered the study between March 
1988 and September 1992. All had invasive breast cancer 
clinically less than 2cm in diameter diagnosed by 
mammography, fine needle aspiration (FNA) cytology or 
trucut biopsy (Travenol Laboratories, Thetford, UK) . 
The mean age of the patients was 55.3 years (range 27- 
81, distribution shown in Graph 1) . One hundred and 
seventy four presented symptomatically and 126 were 
referred through the National Breast Screening 
Programme (69 with palpable lesions).
Illustration 1. Age distribution.
Number
Of
Patients
25 35 45 55
Age
65 75 85
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Surgical Management
A wide local excision was performed with the intention 
of tumour removal with at least l-2cms of surrounding 
macroscopically normal breast tissue. The deep extent 
of the excision was to the pectoral fascia. Tissue
forceps were then applied to the breast tissue lining
the wall of the cavity and this wall was excised 
completely using the scalpel (Illustration 1) and 
labelled "cavity shaving" (CS) . In the light of 
preliminary results, additional random biopsies were 
taken from the wall of the secondary cavity in 165
patients. These were taken by applying tissue forceps 
to the superior, inferior, lateral and medial parts of 
the remaining biopsy cavity wall and excising small
(approximately 1cm) pieces of tissue. These were 
labelled "bed biopsies" (BB). All specimens were 
submitted for histopathology. In all cases the cavity 
shaving was only taken after definitive wide local 
excision of the tumour. In patients with impalpable 
tumours, definitive surgery was performed following 
initial wire-guided diagnostic biopsy.
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Illustration 2. Taking a Cavity Shaving.
Original in colour.
Cavity Shaving
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Pathological Assessment
The maximum diameter of the original lumpectomy 
specimen and the tumour were recorded. Ductal carcinoma 
in situ was described as being absent, minimal, 
moderate or extensive; lymphatic or vascular invasion 
and Bloom and Richardson graded were noted.
The total number of blocks for the cavity shavings 
ranged between 2 0 and 4 0 depending on the specimen 
volume. All tissue was processed. One block was taken 
from each of the bed biopsies. All blocks were serially 
sectioned and the type and extent of disease assessed.
Further Surgery
The decision to offer further surgery on the basis of 
CS or BB involvement with disease was pragmatic and 
related to the pathological findings in each individual 
case. Factors taken into account were the type of 
disease (invasive or in situ) and the extent of disease 
(number of foci and number of blocks involved) . Where 
both CS and BB were positive, further surgery was 
always recommended. Further surgery was also 
recommended if the BB was negative but several foci of 
residual disease were found in the CS. Mastectomy, as 
opposed to wider local excision, was more likely to be 
offered in cases where there was evidence of residual
65
disease involving several blocks, especially when 
extensive residual in-situ disease was present. Patient 
choice and cosmetic factors were also taken into 
account. For instance, mastectomy might be preferred 
when further wide excision would unacceptably 
compromise cosmesis in patients with small breasts.
Adjuvant trea tment
In general, patients who were premenopausal and node­
positive were offered chemotherapy (cyclophosphamide, 
methotrexate and 5-flourouracil) and patients who were 
postmenopausal and oestrogen receptor-positive were 
offered tamoxifen. Intermediate group patients were 
entered into national clinical trials. In addition all 
patients were offered postoperative radiotherapy. This 
consisted of a course of 46Gy in 23 fractions over 35 
days using paired glancing megavoltage fields with a 
boost to the site of local excision of 12 Gy in 4 
fractions over 7 days using 6MEV electrons.
Stastistical analysis
Chi squared tests with Bonferoni correction were used 
to analyse associations of tumour bed positivity with 
clinical and pathological factors where data formed a
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contingency table. The Mann-Whitney test was used to 
analyse association of tumour bed positivity with
patient age, and lumpectomy specimen diameter with
tumour diameter where the comparison of two means was 
required.
RESULTS
Disease was found in the cavity shavings of 118 
patients (39.3%) and in the bed biopsies of 17 patients 
(10.3%) . These results and the type of disease found 
are shown in Table 5. The extent of involvement with 
disease in both the cavity shavings and bed biopsies 
varied widely. Seventy five (63.6%) patients with
positive cavity shavings and 10 (58.8%) patients with
positive bed biopsies had only 1 to 3 foci of disease 
within all the blocks examined. The remaining patients 
had four or more foci. Positivity ranged from one focus 
of ductal carcinoma in situ involving one block to 
extensive invasive disease involving several blocks.
67
Table 5. incidence of disease in Cavity Shavings and
Bed Biopsies.
CAVITY SHAVINGS BED BIOPSIES
Total 300 165
• Invasive only 28 (9.3) 1 (0.6)
• Invasive + In-situ 27 (9.0) 1 (0.6)
• In-situ only 63 (21. 0) 15 (9.1)
TOTAL POSITIVE 118 (39.3) 17 (10.3)
TOTAL NEGATIVE 182 (60.7) 148 (89. 7)
Values in parentheses are percentages.
No patient with negative cavity shavings had a positive 
bed biopsy.
Effect of tumour and lumpectomy diameters
All tumours were 25mm or less in diameter as measured 
pathologically. The median tumour diameter was 13mm and 
the mean lumpectomy specimen diameter was 59mm. To 
determine whether cavity shaving or bed biopsy
positivity was related to tumour size, the patients
were divided into two groups according to tumour 
diameter. One hundred and forty two patients had 
tumours less than 10mm in diameter, 158 had tumours
measuring 10-25mm in diameter. Cavity shaving 
positivity and bed biopsy positivity in relation to
these size groups is shown in Table 6. No statistically 
significant association was observed between tumour 
diameter and cavity shaving or bed biopsy positivity 
(p=0.453 and p=0.083 respectively) although a slight 
trend towards increasing tumour bed positivity with 
increasing tumour diameter was observed.
Of the patients with positive cavity shavings, 4 or 
more foci of residual disease were found in 16 of 53 
tumours smaller than 10mm (30.2%) and 27 of 65 tumours 
between 10 and 25 mm (41.5%).
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Table 6. Effect of tumour diameter on tumour bed 
positivity.
TUMOUR DIAMETER 
(mm)
Positive Cavity 
Shavings
Positive Bed 
Biopsies
0-9 53 (37.3) 5 (7.6)
10-25 65 (41.1) 12 (14.3)
Values in parentheses are percentages.
The mean diameters of the lumpectomy specimens were 
correlated with the median tumour diameters in the two 
groups of patients and then sub-divided into whether or 
not the cavity shavings were positive or negative. 
There was no statistically significant correlation 
between the mean lumpectomy diameter and tumour bed 
positivity (Table 7, p=0.283). However there was a
trend for cavity shaving and bed biopsy positivity to 
be associated with a smaller lumpectomy diameter for 
tumours less than 10mm in diameter.
70
Table 7. Relationship between tumour bed positivity and
diameter of lumpectomy specimen.
TUMOUR DIAMETER 
(mm)
MEAN LUMPECTOMY SPECIMEN DIAMETER 
(mm)
Cavity Shavings 
Positive Negative
Bed Biopsies 
Positive Negative
0 - 9 53 58 43 57
10 - 25 61 63 63 63
Association with screen-detected and impalpable tumours
There was no statistically significant difference in 
cavity shaving positivity between symptomatic and 
screen-detected tumours or screen-detected palpable and 
impalpable tumours. However, tumour-bed positivity was 
less frequent in patients with impalpable screen- 
detected tumours (Table 8).
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Table 8. Incidence of positive Cavity Shavings among
patients with symptomatic and screen-detected tumours.
Total POSITIVE CAVITY SHAVINGS
Symptoma ti c 174 75 (43.1)
Screen-detected
• Palpable 69 25 (36.2)
• Impalpable 57 18 (31.6)
Values in parentheses are percentages.
Effect of patient age
The relationship between cavity shaving positivity and 
patient age is shown in Tables 9 and 10. The mean age 
of patients with positive cavity shavings or bed 
biopsies was lower than those with negative cavity 
shavings or bed biopsies (non-significant p=0.08/ Table 
9) .
When patients were divided into age groups the greatest 
incidence of tumour bed positivity was found in the 35 
to 49 years group and the smallest incidence in the 
over 65 group (Table 10). To assess whether the extent
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of surgery was influenced by age the mean lumpectomy 
diameters were compared for different age groups. The 
mean lumpectomy diameter tended to be larger in older 
patients (Table 10).
Table 9. Relationship between patient age and tumour 
bed positivity.
MEAN AGE (years)
Positive Cavity Shavings 53.9
Negative Cavity Shavings 56.2
Positive Bed Biopsies 51.2
Negative Bed Biopsies 55.2
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Table 10. Relationship between patient age groups and
cavity shaving positivity and lumpectomy diameter.
AGE (years)
27-34 35-49 50-64 Over 65
Positive Cavity 
Shavings
4 of 11 
(36.4)
31 of 59 
(52.5)
70 of 188 
(37.2)
13 of 42 
(31.0)
Positive Bed 
Biopsies
0 of 6 
(0)
8 of 34 
(23.5)
8 of 104 
(7.7)
1 of 19 
(5.3)
Median Tumour 
Diameter (mm)
15 15 10 15
Mean Lumpectomy 
Diameter (mm)
56 57 59 64
Values in parentheses are percentages.
Effect of tumour grade, lymphatic/vascular invasion and 
in-situ component.
Cavity shaving positivity was significantly associated 
with tumour grade (p=0.023, Table 11) . The highest 
incidence of cavity shaving positivity was found with 
Grade II tumours. There were 42 tumours that were non- 
ductal and hence ungraded. Of these, 19 were classified 
as lobular. The incidence of cavity shaving positivity
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for lobular carcinomas was 47.4%. Cavity shaving 
positivity was not significantly related to the 
presence of lymphatic or vascular invasion within the 
tumour (Table 11).
Table 11. Relationship between Cavity Shaving 
positivity and tumour grade and lymphatic/vascular 
invasion.
Total POSITIVE CAVITY 
SHAVINGS
Tumour Grade 1 72 19 (26.4)
2 145 69 (47.6)
3 41 15 (36. 6)
Ungraded 42 15 (35.7)
Lympha ti c/Va s cular Present 52 22 (42.3)
Invasion
Absent 248 96 (38. 7)
Values in parentheses are percentages.
To analyse the association between in-situ component 
and tumour bed positivity, tumours with a moderate or
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extensive in-situ component were grouped as EIC and 
compared with those with minimal or no in-situ 
component (grouped as no EIC). Fifty-two patients 
(17.3%) had tumours with EIC. Both cavity shaving and 
bed biopsy positivity were significantly related to the 
presence of EIC (p<0.001, Table 12). Further analysis 
showed that EIC was associated with in-situ disease in 
the tumour bed.
The presence of an in-situ component varied with age. 
For patients with no EIC the mean age was 56.0 years 
whereas the mean age of patients with EIC was 51.8 
years (p=0.21).
Association with axillary lymph node metastases
A total of 253 patients had a level two axillary 
dissection performed of whom 68 (26.9%) were node
positive and 185 (73.1%) were node negative. No
significant association was found between tumour bed 
positivity and axillary nodal status (p=0.827) or 
number of nodes involved (table 13).
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Table 12. Relationship between tumour bed positivity
and In-situ component of the tumour.
Total MODERATE /EXTENSIVE 
IN-SITU COMPONENT
CAVITY SHAVINGS
• Invasive only 28 2 (7.1)
• Invasive + In-situ 27 12 (44 .4)
• In-situ only 63 18 (2 8 . 6)
Total Positive 118 32 (2 7 .1)
Total Negative 182 20 (11.0)
BED BIOPSIES
Positive 17 7 (41.2)
Negative 148 16 (10.8)
Values in parentheses are percentages.
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Table 13. Relationship between tumour bed positivity
and axillary lymph node status.
Total LYMPH NODE POSITIVE
Overall 1-3
nodes
positive
4 or more 
nodes 
positive
CAVITY SHAVINGS
• Invasive only 24 10 8 2
(41.7) (33.3) (8.3)
• Invasive + In-situ 25 7 6 1
(28. 0) (24.0) (4.0)
• In-situ only 51 12 11 1
(23.5) (21.6) (2.0)
Total Positive 100 29 25 4
(29. 0) (25.0) (4.0)
Total Negative 153 39 33 6
(25.5) (21. 6) (3.9)
BED BIOPSIES
Positive 14 3 (21.4)
Negative 133 33 (24.8)
Values in parentheses are percentages.
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Inter-surgeon variability and tumour bed positivity
Three surgeons with specialist breast interests 
(consultant, a staff grade and a senior registrar) 
performed 79% of the operations. The rate of cavity 
shaving positivity for these surgeons varied from 38.2 
to 45.8% (p=0.67). The remainder of the operations were 
performed by 2 senior registrars and 2 registrars and 
the rate of cavity shaving positivity among these 
surgeons varied from 25 to 38.9% (p=0.61) . The
variation in tumour and lumpectomy diameter between 
different surgeons is shown in table 14.
Table 14. Inter-surgeon variability
Median
Tumour
Diameter
Mean
Lumpectomy
Diameter
Tumour Bed 
Positivity
Surgeon 1 13 57 61/157 (38.9%)
Surgeon 2 13 57 22/48 (45.8%)
Surgeon 3 12 61 13/34 (38.2%)
Others 13 64 22/61 (36.1%)
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Further surgery
Further surgery was performed on 41 patients because of 
extensive disease involving cavity shavings, bed 
biopsies or both. Eight had further wide local excision 
and 33 patients underwent mastectomy. Further invasive 
cancer was found in 12 patients and further in-situ 
disease in 10 patients. Altogether 53.7% of patients 
who underwent further surgery had evidence of further 
residual disease.
Further residual disease was more likely to be found if 
an extensive in-situ component was present in the 
tumour (66.7%), 4 or more foci were present in the
cavity shavings (58.3%) and if both the cavity shavings 
and bed biopsies were positive (72.7%).
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DISCUSSION
This study has demonstrated a 39.3% incidence of tumour 
bed positivity after conventional breast-conserving 
surgery for early breast cancer. In 21% of patients
residual disease was purely in-situ and in 18.3% there 
was an invasive component. No significant association 
between tumour bed positivity and tumour diameter was 
found. These findings are consistent with those of the 
pathological study by Holland et al in which residual 
disease was found beyond 2cm from the primary tumour in 
43% of mastectomy specimens. In 27% of specimens this 
disease was in-situ and in 16% there was an invasive
component^. Holland et al also found that residual 
disease was independent of tumour size^.
The extent of disease within positive cavity shavings 
was not significantly related to tumour size although 
41.5% of 10-25mm tumours with positive cavity shavings 
had 4 or more foci of residual disease compared to 30% 
of tumours less than 10mm. Since the spatial
orientation of the tumour within the lumpectomy 
specimen is not known no comment can be made on the
incidence of residual disease at precise distances from 
the tumour edge. However, to assess whether tumour bed 
positivity was related to lumpectomy size the mean 
lumpectomy diameter was correlated with tumour bed
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positivity for varying tumour size groups. No 
significant association was found suggesting that a 
standard surgical procedure was carried out on all 
patients although there was a trend for tumour bed 
positivity to be associated with a slightly smaller 
mean lumpectomy diameter.
The incidence of tumour bed positivity among screen- 
detected patients was 34.1%. This is an important group 
of patients who might be expected to have a 30% 
survival advantage over the non-screened population^®. 
They are likely to be node-negative and adequacy of 
local treatment may be particularly significant for 
these patients.
Tumour bed positivity was significantly associated with 
both tumour grade and the presence of a moderate or 
extensive in-situ component. High tumour grade and an 
extensive in-situ component (EIC) have generally been 
found to predict for an increased risk of local 
recurrence. EIC was originally defined as present if 
greater than 25% of the tumour consisted of in-situ 
carcinoma and in-situ disease was present around the 
tumour. Different definitions of EIC have been used by 
other investigators. The reported incidence of EIC 
varies from 6.7% in the Milan trials to 30% in the 
series of mastectomy specimens studies by Holland et 
aj47, 79. jn this study EIC was defined as absent,
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minimal, moderate or extensive. Patients with a 
moderate in-situ component were grouped with those who 
had an extensive component (collectively termed EIC) 
due to the small numbers of patients in the latter 
category. In all, 1 7 . 3 %  of patients had EIC. It was 
strongly associated with residual in-situ disease in 
the tumour bed but did not correlate with residual 
invasive disease. In the study by Holland et al tumours 
with EIC were associated with a 5 9 %  incidence of 
disease at a distance greater than 2cm from the tumour 
edge compared to 2 9 %  of those without EIC^9. As with 
the present study, this significant difference was 
attributable to a strong association between EIC and 
diffuse in-situ disease.
The mean age of patients did not vary significantly 
with tumour bed positivity. However, the mean age of 
patients who had a positive tumour bed tended to be 
younger than those with a negative tumour bed. The mean 
lumpectomy diameter also tended to be smaller for 
younger patients possibly due to the greater concern 
regarding cosmesis in this group. A study analysing 
tumour bed positivity by documenting disease in re­
excision specimens performed for involved or unknown 
margins found no association between age and residual 
disease^, other studies have correlated very young age 
with a high incidence of local recurrence^. This has 
been attributed to the association between young age
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and EIC^S. in this study the mean age for patients with 
EIC was 4 years less than that of patients with no EIC 
(not statistically significant).
Previous investigators have suggested that local 
recurrence is related to axillary lymph node positivity 
and that inoperable local recurrences tend to occur in 
patients who are node-positive^' 109# jn this study no 
significant relationship was found between tumour bed 
positivity and lymph node status.
The decision to offer further surgery was pragmatic and 
was influenced by many variables. Analysis of the 
predictors for further residual disease is therefore 
limited by this fact. However, an extensive in-situ 
component, 4 or more foci in the cavity shavings and 
bed biopsy positivity were all associated with an 
increased incidence of further residual disease.
In summary, shaving the tumour bed is a practical 
method to assess completeness of surgical excision. Any 
disease found in the tumour bed is undoubtedly residual 
disease. The cavity shaving specimen is easily 
processed and embedded blocks and sections do not 
require orientation relative to a cut surface. This 
study has shown that the incidence of residual disease 
after conventional breast-conserving for invasive 
breast cancer is 39.3%. This incidence closely 
approximates that predicted by studies simulating
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lumpectomy in mastectomy specimens. Statistically 
significant risk factors for tumour bed positivity 
found in this study are high tumour grade and a 
moderate or extensive intraduct component. However an 
increased incidence of tumour bed positivity was also 
found with young age, lobular carcinoma and small 
lumpectomy diameter.
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CHAPTER 2
INTRODUCTION
Mammography is a mandatory pre-operative investigation 
in all patients undergoing surgery for breast cancer. 
For patients considered suitable for breast-conserving 
surgery mammography has an established role to detect 
clinically occult multifocal d i s e a s e H O ' m . Such 
patients are more likely to require mastectomy. A few 
studies have assessed mammography as a method of 
predicting risk for local r e c u r r e n c e ® ^ / 112-113  ^ This is 
possible if mammographic features are shown to 
correlate with pathological risk factors for local 
recurrence. As discussed previously the main 
pathological risk factors for local recurrence are 
residual disease at the resection margin, an extensive 
intraduct component, lymphatic or vascular invasion and 
high tumour grade. Pre-operative identification of risk 
factors for local recurrence may influence the extent 
of primary excision and limit the need for further 
surgery.
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Previous studies have concentrated on the value of 
post-operative mammography to detect residual disease 
at the resection marginH2-114 ^ However, the 
interpretation of post-operative mammography is 
difficult and inaccurate due to distortion created by 
the surgical scar^^^-^. Other investigators have 
established that certain mammographic features such as 
mammographic calcifications and absence of mammographic 
nidus predict for the presence of an extensive 
intraduct component in the tumour*^'115^
The study presented in this chapter was designed to 
answer the following questions:
• Can pre-operative mammography predict patients more 
likely to have microscopic disease in the tumour 
bed after breast-conserving surgery?
• Can pre-operative mammography identify patients 
with pathological risk factors for local 
recurrence?
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PATIENTS AND METHODS
Patients
Of the 300 patients with pathological analysis of 
tumour bed presented in Chapter One, 231 had pre­
operative mammograms available for review. The study 
population consisted therefore of 231 patients who 
presented between March 1988 and September 1992 with 
invasive breast cancer suitable for breast-conserving 
surgery. The mean age of these patients was 56 years 
(range 27-80). One hundred and twenty patients 
presented symptomatically while 111 presented through 
the National Breast Screening Programme.
Mammogram interpretation
Bilateral craniocaudal and oblique mammograms were 
performed pre-operatively on each patient. The 
following features were recorded: Wolfe grade116 (Nl,
PI, P2 or DY) , nidus size (mm), nidus type (round, 
stellate, absent), tumour calcification (casting, non­
casting or absent), maximum diameter of mammographic 
abnormality (nidus diameter plus diameter of 
surrounding distorted of breast architecture), nidus to 
nipple distance and nidus location (quadrant). All
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mammograms were reported by a specialist breast 
radiologist without knowledge of pathological results.
Surgical management and pathological assessment
The surgical management and pathological assessment of 
specimens has been previously described (Chapter One).
Statistical analysis
The Chi squared test with Bonferroni correction was 
used to analyse possible associations between 
mammographic features and pathological factors where 
data formed a contingency table. The two sample T test 
was used to analyse possible associations between 
mammographic features and pathological factors where 
comparison of two means was required.
RESULTS
Correlation of mammographic features with tumour bed 
positivity
There was no evidence of residual disease in the cavity 
shavings for 138 patients. Microscopic foci of residual
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invasive disease were found in 44 patients (19%) and 
in-situ disease in 49 patients (21.2%).
The presence of residual disease in the cavity shavings 
was correlated with pre-operative mammographic 
features. Disease in cavity shavings was significantly 
associated with DY compared with Nl mammographic 
pattern on Wolfe grade (p=0.03, Table 15), casting-type 
calcification compared with either non-casting or 
absence of calcification (p=0.02 and p<0.001 
respectively, Table 16) and absence of mammographic 
nidus compared with either stellate or round nidus 
(p=0.05 and pcO.OOl respectively, Table 17).
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Table 15. Association between Wolfe Grade and cavity
shaving positivity.
Total POSITIVE CAVITY SHAVINGS
Wolfe Grade
• Nl 3 3 8  (24 .2)
(no visible ducts)
• PI 5 0 1 6  (32 .0)
(<25% ducts visible)
• P2 7 8 3 4  (43.6)
(>25% ducts visible)
• DY 7 0 3 5  (50.0)
(ducts obscured by 
density of breast)
Values in parentheses are percentages
Table 16. Association between mammographic 
calcification and cavity shaving positivity.
Total POSITIVE CAVITY SHAVINGS
Tumour Calcification
• Casting 4 3 2 9 (67.4)
• Non-casting 4 2 1 6 (38 .1)
• Absent 1 4 6 4 8 (32 .9)
Values in parentheses are percentages.
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Table 17. Association between type of mammographic
nidus and cavity shaving positivity.
Total POSITIVE CAVITY SHAVINGS
Type Of Nidus
• Round 98 2 9 (29.6)
• Stellate 114 50 (43.9)
• Absent 19 14 (73.7)
Values in parentheses are percentages.
Disease in the cavity shavings was found in 75-88.9% of 
patients when DY pattern, casting calcification or 
absent mammographic nidus were identified in 
combination on the pre-operative mammogram (Table 18 
and Illustration 3) . In patients with Nl mammographic 
pattern, absence of calcification and round 
mammographic nidus, disease in the cavity shavings was 
found in 13.3% of cases (Illustration 4).
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Table 18. Combinations of mammographic features
predicting cavity shaving positivity.
Total POSITIVE CAVITY 
SHAVINGS
COMBINATION
• Casting calcification + 
absent nidus
1 2 9  (75.0)
• DY pattern + casting 
calcification
1 2 1 0  (83.3)
• DY pattern + absent nidus 9 8  (88.9)
Values in parentheses are percentages.
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Illustration 3. Mammographic features predicting cavity
shaving positivity.
DY Wolfe pattern, casting - type calcification, 
no mammographic nidus
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Illustration 4. Mammographic features predicting cavity
shaving negativity.
NI Wolfe pattern, no calcification, 
round mammographic nidus
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There were no significant associations between disease 
in the cavity shavings and nidus size, maximum diameter 
of mammographic abnormality, nidus to nipple distance 
(Table 19).
Table 19. Association between cavity shaving positivity 
and nidus size, maximum diameter of mammographic 
abnormality and nidus to nipple distance.
NEGATIVE
CAVITY
SHAVINGS
POSITIVE
CAVITY
SHAVINGS
• Nidus size (mean in mm) 16 16
• Maximum diameter mammographic 
abnormality (mean in mm)
39 37
• Nidus to nipple distance on 
craniocaudal film (mean in 
mm)
79 77
• Nidus to nipple distance on 
oblique film (mean in mm)
80 77
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Correlation of mammographic features with intraduct
component of the tumour.
As in Chapter One, tumours with a moderate or extensive 
intraduct component were compared with those with 
minimal or no intraduct component. The presence of a 
moderate or extensive intraduct component was 
significantly associated with both casting and non­
casting mammographic calcification compared with 
absence of mammographic calcification (p<0.001 and 
p=0.04 respectively, Table 20). A significant 
relationship was also found between the absence of 
mammographic nidus and a stellate nidus compared with a 
round nidus (p<0.001 and p=0.02 respectively, Table 
21) .
A moderate or extensive intraduct component was found 
in 32.6% or 70.6% of patients when tumour calcification 
and stellate mammographic nidus or absence of 
mammographic nidus were identified together on the pre­
operative mammogram (Table 22 and Illustration 4) . In 
patients with absence of calcification and a round 
mammographic nidus it was found in 8.2% of cases 
(Illustration 5). There were no significant 
associations between the degree of intraduct component 
and Wolfe grade, nidus size, maximum diameter of 
mammographic abnormality, nidus to nipple distance or 
nidus location.
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Table 20. Association between mammographic tumour
calcification and the in-situ component of the tumour.
Total MODERATE/EXTENSIVE IN-SITU 
COMPONENT
Tumour Calcification
• Casting 43 19 (44.2)
• Non-Casting 42 12 (28. 6)
• Absent 146 20 (13.7)
Values in parentheses are percentages.
Table 21. Association between type of mammographic
nidus and in-situ component of the tumour.
Total MODERATE/EXTENSIVE IN-SITU 
COMPONENT
Type Of Nidus
• Round 100 11 (11.0)
• Stellate 114 28 (24.6)
• Absent 17 12 (63.2)
Values in parentheses are percentages.
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Table 22. Combinations of mammographic features
predicting for in-situ component in the tumour.
Total MODERATE / 
EXTENSIVE IN- 
SITU COMPONENT
COMBINATION
• Tumour Calcification + 
Stellate Nidus
43 14 (32.6)
• Tumour Calcification + 
Absent Nidus
17 12 (70.6)
Values in parentheses are percentages.
Other associations
There were no significant associations between 
mammographic features and lymphatic/vascular invasion, 
tumour grade or tumour type (ductal versus lobular).
Wolfe grade was significantly related to age (p<0.001) 
such that a dense mammographic pattern was more common 
in younger patients (Table 23). The mean maximum 
diameter of the lumpectomy specimen also varied 
significantly with Wolfe grade from 64mm in N1 patients
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to 54min in DY patients (N1 versus DY p=0.039, Table 
23) , whereas the mean tumour diameter did not vary 
significantly.
Table 23. Association of age, mean lumpectomy diameter 
and tumour diameter with Wolfe grade.
WOLFE GRADE
N1 PI P2 DY
Mean Age (years) 60.8 58.0 56.3 51.8
Mean Lumpectomy Diameter (mm) 64 60 57 54
Mean Tumour Diameter (mm) 12 12 12 13
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DISCUSSION
This study used pre-operative mammograms to identify 
mammographic features that correlate with residual 
disease and other pathological risk factors for local 
recurrence. It has demonstrated that DY mammographic 
pattern, casting calcification and absence of 
mammographic nidus are associated with a significantly 
increased risk of residual disease (50-73.7%) and a 
combination of these features predicts residual disease 
in 75-88.9% of cases. Conversely, patients with N1 
mammographic pattern, absence of calcification and 
round mammographic nidus are at low risk of residual 
disease (24.2-32.9%) and when all these features are 
present residual disease is found in 13.3% of cases.
Previous reports correlating residual disease with 
mammographic features have been small studies relating 
the appearances of post-operative mammograms to disease 
found in re-excision s p e c i m e n s l l 2 - 1 1 4 # jn a study of 4 3  
patients, Gluck et al demonstrated that mammographic 
calcifications detected on post-operative films were 
associated with residual disease in 69% of re-excision 
specimens compared with 3 0 . 8 %  with no remaining 
mammographic calcificationsl1^. other studies have 
shown however, that the appearances of up to 5 0 %  of 
post-operative mammograms may be inaccurately
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interpreted due to biopsy-related distortion or oedema, 
rendering post-operative mammography an insensitive
method of detecting residual disease-*-10' llz^ #
This study has demonstrated that despite similar tumour 
diameters, patients with DY pattern (Wolfe grade) had a 
significantly smaller amount of breast tissue excised 
than patients with N1 pattern. The Wolfe grading system 
was originally described as a means to categorise the 
parenchymal patterns of the breast as they appear
mammographically110. An N1 pattern exists when no ducts 
are visible, a PI pattern is present when less than 25% 
of the breast is composed of "prominent ducts", a P2 
pattern has more than 25% "prominent ducts" and a DY 
pattern is defined by sheet-like areas of increased 
density obscuring the underlying duct pattern.
Subsequent studies have shown that these patterns are 
related to the distribution of fibrous and adipose 
tissue in the breast117. Breasts with a N1 pattern are 
composed primarily of fat and those with a DY pattern 
are dense and fibrous. It has been previously reported 
that agreement on the classification of mammographic 
pattern between radiologists is generally very good. 
Hence in the present study all mammograms were reported 
by one consultant breast radiologist110-120. The 
association between Wolfe grade and tumour bed 
positivity suggests that there may be a tendency to
excise a relatively smaller margin of macroscopically
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normal breast tissue in patients with dense fibrous 
breasts in whom the tumour edge may not be easily 
palpable. This may partly explain the increased risk of 
local recurrence in younger patients observed in some 
studies^.
Tumours with a large intraduct component, lymphatic or 
vascular invasion and high tumour grade also predict 
for local recurrence. Previous investigators have shown 
that the extent of the intraduct component correlates 
with mammographic calcification and absence of 
mammographic nidus87,H5. Healey et al reported that 
73% of patients with mammographic calcifications and 
absent mammographic nidus had tumours with an extensive 
intraduct component (EIC) . Only 8% of patients had 
tumours with EIC if a mammographic nidus was present 
without calcifications87• The present study has shown 
that mammographic tumour calcification without a 
mammographic nidus is associated with a 70.6% incidence 
of tumours containing a moderate or extensive intraduct 
component. Only 8.2% of tumours had a large intraduct 
component if a round mammographic nidus was present 
without calcification. This study was unable to 
demonstrate any association between mammographic 
features and tumour grade or the presence of 
lymphatic/vascular invasion.
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In summary, certain features identified on pre­
operative mammograms may predict patients who are 
likely to have residual disease after breast-conserving 
surgery and have tumours with a large intraduct 
component. Combinations of these features can identify 
small numbers of patients at particularly high or low 
risk of local recurrence. In high risk patients a wider 
primary excision may be indicated or alternatively, in 
some cases a patient may be deemed unsuitable for 
breast-conserving surgery.
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CHAPTER 3
INTRODUCTION
Many biological factors associated with breast cancer 
have been shown to correlate with outcome after 
surgery. Three of the most established factors of 
prognostic interest are c-erbB-2, p53 and the oestrogen 
receptor.
C-erbB-2
C-erbB-2 is an oncogene located at 17q21.2-12 that 
codes for a 185 kDa transmembrane protein growth factor 
receptor (pi85) . P185 is a member of the type 1 family 
of growth factor receptors, which also includes c-erbB- 
3 and c-erbB-4. C-erbB-2 is similar to, but distinct 
from c-erbB-1, an oncogene located on chromosome 7 that 
codes for the epidermal growth factor receptorl^l. The 
pl85 protein is a normal constituent of cytoplasmic 
membranes and has some intracellular tyrosine kinase 
activity. The natural ligands for this receptor are 
under investigation. The neu differentiation factor
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appears to play an important role and pl85 and EGFR may 
co-operate as heterodimers upon ligand binding122, 
has been shown that EGF can indirectly activate pl85 
via activation of EGFR, which mediates tyrosine 
phosphorylation of pl85122. j-j- j_s possible that this 
interaction between EGF and pl85 is limited to a few 
cells that express the two receptors simultaneously124  ^
Experimental evidence suggests that pl85 may have an 
important role in the pathogenesis of breast cancer and 
overexpression of c-erbB-2 alone is sufficient to 
support mammary carcinoma in transgenic m i c e 1 2 ^.
Amplification and over-expression of the c-erbB-2 
oncogene detected by Southern and Northern blotting 
have been shown to correlate with c-erbB-2 oncoprotein 
expression evaluated by Western blotting and 
immunohistochemistry suggesting that
immunohistochemistry is a valid method for evaluating 
c-erbB-2 in archive breast cancer s p e c i m e n s 1 2 ^ .
Moderate to low levels of pl85 are found in normal 
breast although activation of c-erbB-2 has not been 
found in benign breast lesions. The physiological 
action of c-erbB-2 in normal breast is unknown although 
it is believed to be related to the differentiation of 
the breast124. Amplification of the gene with 
overexpression of pl85 is found in approximately 20% of 
breast cancers. It varies with histological subtype
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such that amplification is found in approximately 22% 
of ductal carcinomas, 7% of lobular carcinomas, 7% of 
tubular carcinomas, 62% of inflammatory carcinomas and 
22% of medullary carcinomas137 .
Over-expression of pl85 is found in the great majority 
(68-90%) of patients with comedo-type DCIS, whilst 
overexpression is extremely uncommon in other types of 
DCIS13 .^ a  significant association with tumours 
containing an intraduct component has also been found. 
One study found that 13/21 (62%) of patients staining
positively for c-erbB-2 had an intraduct component 
compared to 31/86 (36%) of those staining
negatively13^b jn a larger study, 51/97 (52.6%) of
patients who stained for c-erbB-2 had a significant 
intraduct component compared to 237/412 (33.7%) of
those who stained negatively13^. jn ^he latter study 
there was concordance of overexpression between the 
invasive and in-situ components of the tumour in all 
but two cases, where only the in-situ component stained 
positively. The increased expression of c-erbB-2 in in- 
situ breast cancer partly supports the hypothesis that 
activation of c-erbB-2 is an early event in the 
development of breast cancer.
An association between poor nuclear or histological 
grade and overexpression of c-erbB-2 has been found131- 
133. There are also conflicting reports associating
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overexpression of c-erbB-2 with young age, oestrogen 
receptor negative and progestogen receptor negative 
tumours, high proliferative index and large tumour 
size-*-270 Over-expression is associated with a poor 
response to endocrine and conventional cytotoxic drug 
therapy-l-36-l-3*3.
C-erbB-2 was first shown to have clinical significance 
in 1987 by Slamon et al who reported that amplification 
was associated with decreased survival in node-positive 
patientsl39. a large number of groups have now 
published data concerning the prognostic significance 
of c-erbB-2l40. Of these, very few have failed to find 
any prognostic effect. A minority have found that c- 
erbB-2 has a prognostic effect in both recurrence-free 
and survival analyses which is maintained in 
multivariate analysis13! 132,141# However, most studies 
have found that the prognostic effect of c-erbB-2 is 
stronger for survival than it is for 
r e c u r r e n c e 1 3 ^ 131,132,136 ancj SOine studies have shown 
an effect on survival but no effect on recurrence1^ . 
Most studies have shown that the prognostic value of c- 
erbB-2 is greater for node-positive patients but this 
may reflect the relatively large number of patients 
required to show a prognostic effect in node negative 
groupsl-32. Within a large study comparing breast- 
conserving surgery with mastectomy Sauer et al 1992 
found c-erbB-2 to predict for distant disease-free
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survival in node-positive and node-negative
p a t i e n t s l 4 2  #
Two studies have related c-erbB-2 over-expression to 
local recurrence following surgery for breast cancer. 
One study found that 1/6 (17%) of c-erbB-2 positive
tumours developed chest wall recurrence compared to 
6/15 (40%) of c-erbB-2 negative tumours^^. Another
study found that 2/21 (10%) of c-erbB-2 positive
patients developed local recurrence after conservation 
surgery compared to 16/84 (19%) of c-erbB-2 negative
patients!29^ jn ^he latter study, local failure rates 
following mastectomy were equal for c-erbB-2 positive 
and c-erbB-2 negative patients (both 13%).
p53
The p53 gene was discovered in 1979143  ^ is located 
on the short arm of chromosome 17 at position 17pl3.1 
and encodes for a 393 amino acid, 53 kda nuclear 
phosphoprotein (p53). This protein is present at very 
low levels in normal tissues that cannot usually be 
detected by conventional immunohistochemical methods. 
The normal (wild type) p53 gene inhibits cellular 
transformation by oncogenes, acting as a tumour 
suppressor gene, although the mechanism by which it
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perforins this protective role is not fully understood. 
The p53 protein appears to act by monitoring the genome 
and minimising the mutations that arise from exposure 
to DNA-damaging agents. It may bind to cellular or 
viral proteins and promote cytoplasmic
sequestration144. Increased levels of p53 protein are 
found in tissue exposed to various DNA damaging agents 
such as UV and gamma radiation. It may block the 
division of cells that have sustained DNA damage and in 
some cases trigger cell death by apoptosis145-147.
Failure of p53 to exert its tumour suppressive function 
may occur if there is loss of heterozygosity (loss of 1 
allele) or homozygous deletion (loss of both alleles) 
of the p53 gene. This is the most common genetic change 
detected in a wide range of human cancers. In breast 
cancer loss of heterozygosity occurs in 42 - 61% of
tumours but homozygous deletion is very rare. In 
addition, mutant forms of p53 are commonly expressed in 
tumour cells (occurring in 15 - 46% of breast cancers) 
and some of these have oncogenic properties with the 
ability to immortalise cells in culture145-147. Germ 
line mutation of p53 is a rare event in patients with 
sporadic or familial breast cancer except in the Li- 
Fraumeni syndrome in which inherited p53 mutation leads 
to a variety of tumours including breast cancer14 .^
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The wild type p53 protein has a very short half life of 
approximately 2 0  minutes. It is thought that point 
mutations in the p53 gene cause accumulation of the p53 
protein by increasing its stability (and hence its half 
life), and in most cancers p53 mutation is accompanied 
by increased amounts of p53 protein which is detectable 
using immunohistochemical staining. Immunostaining of 
p53 protein in tumours is usually confined to the 
nucleus. A wide variation in the percentage of breast 
cancers staining positive for p53 protein has been 
reported although most large studies have shown 
definite staining in approximately 2 0 %  of t u m o u r s ^ 9  ^
In breast cancer it appears that a second region on 
17pl3, distinct from p53 may exert an influence over 
p53 expression. This may partially explain the 
discrepancy that exists between the loss of 
heterozygosity, the rate of p53 mutation and the 
frequency with which p53 protein is d e t e c t e d ! 4 2 - 1 4 7 # 
Increased expression of wild type p53 protein can also 
occur as a consequence of p53 mutation and excessive 
amounts of wild type as well as mutant protein may be 
detected immunohistochemically. In addition, the method 
of fixation can influence the stability of p53 protein 
and tumours often show marked heterogeneity of staining 
for p53 protein, which may cause sampling error1^ .
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Mutations that result in deletion or truncation of the 
protein (nonsense and frameshift mutations) do not 
cause protein accumulation. In addition,
immunohistochemical positivity can occur in the absence 
of mutation. One mechanism for this is the 
stabilisation of non-mutant p53 protein by cellular 
oncoproteins such as MDM-2 (mouse double minute 2) 151.
p53 is known to regulate MDM-2 gene transcription and 
it is believed that interaction between MDM-2 and p53 
is necessary to maintain controlled cell growth!52#
In general, however, there is good concordance between 
immunohistochemical positivity and mutation in
conserved regions of the p53 gene. Molecular analysis 
can be employed to detect gene mutations using rapid 
PCR-based mutation screening procedures such as single­
strand conformation polymorphism. Alternatively DNA
sequencing of the entire coding region can be
performed. Sequencing is probably the most sensitive 
method but its use is limited by its expense and need 
for relatively pure tissue samples.
In breast cancer patients associations have been found 
between p53 mutations or overexpression of p53 protein 
and ER negative and PR negative tumours, EGFR positive 
tumours, high tumour grade, increased proliferation 
index, metastatic disease, a poor response to
chemotherapy and decreased disease-free and overall
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survival1^-! 61 ^ studies have shown no association 
between overexpression of p53 and overexpression of c- 
erbB-2-*-42, 162 #
p53 protein overexpression also appears to be 
associated with comedo-type DCIS163/ 164 # jn one study 
p53 was overexpressed in 34/95 cases of comedo-type 
DCIS compared to 2/48 cases of non-comedo DCIS16 .^ This 
has led to the suggestion that p53 abnormalities may 
occur as an early event in breast carcinogenesis and 
may play a role in the malignant transformation of 
DCIS.
Oestrogen receptor
In 1896, Beatson observed regression of metastatic 
breast cancer in premenopausal women following 
oophorectomy16^. Over fifty years later a similar 
beneficial response was reported in postmenopausal 
women after adrenal gland ablation166. However 
oestrogen receptors were not recognised until 1971 when 
Jensen et al correlated the response to adrenalectomy 
with the specific binding of oestradiol in tumour 
sections16^.
113
High affinity cytoplasmic oestrogen receptors (ER) bind 
circulating oestrogen. This hormone-activated receptor 
complex is translocated into the breast cancer cell 
nucleus where it promotes specific gene transcription. 
Oestrogen receptor positivity increases with age. 
Tumours with poor differentiation, high histological 
grade, high proliferative index and extensive necrosis 
are more likely to be ER negative. ER positive tumours 
are more likely to be well differentiated with low 
histological grade and low proliferative indexes. No 
consistent association between ER positivity and tumour 
size, vascular or lymphatic invasion, intraduct 
component or axillary lymph node status has been found.
Many studies have shown a correlation between ER status 
and distant disease-free and overall survival with ER 
negative tumours associated with poor outcome^69- This 
correlation does not appear to be dependent on adjuvant 
hormonal therapy. It has also been suggested that ER 
positivity loses its prognostic power with long follow- 
up and that it is related to the growth rate of the 
tumour rather than its metastatic p o t e n t i a l ^ O .
ER status did not affect the incidence of local 
recurrence in the NSABP B-06 or the NCI trials-^'^9* 
Other studies have found a small but non-significant 
association between ER negative tumours and local 
recurrence^' •
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C-erbB-2, p53 and ER are therefore, established 
prognostic factors in breast cancer. Both c-erbB-2 and 
p53 are strongly associated with comedo DCIS. This is 
known to predict for margin involvement and local 
recurrence after breast conserving surgery. In addition 
all of these factors are associated with high tumour 
grade, which is again strongly associated with local 
recurrence. C-erbB-2, p53 and ER can all be assessed in 
needle biopsy specimens and their status could 
theoretically therefore be determined preoperatively. 
If an association was found between tumour bed status 
and these factors then they may be helpful in 
preoperative selection of patients for breast- 
conserving surgery.
This study presented in this chapter was designed to 
answer the following question:
• Is the incidence of residual disease related to 
known biological prognostic factors (ER, p53, c-erbB- 
2 ) ?
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PATIENTS AND METHODS
Patients
Of the 300 patients presented in chapter one, 253 had 
archival tissue fixed in paraffin available for 
immunohistochemical staining. Oestrogen receptor 
analysis was performed at the time of surgery for 275 
patients.
Statistics
Associations between tumour bed positivity and 
oestrogen receptor, c-erbB-2 and p53 status were 
analysed for statistical significance using the chi- 
squared test with Bonferoni correction.
Antibodies
The c-erbB-2 antibody used was NCL-CB11 (Novocastra 
Laboratories Ltd, Newcastle upon Tyne) at 1:20 
dilution. This monoclonal antibody has been shown to 
give intense membrane staining for c-erbB-2 protein in 
paraffin fixed tissue^-*-. The p53 antibody used was DO- 
1 (Donated by David Lane, Biochemistry Department, 
University of Dundee) at 1:1000 dilution.
116
Oestrogen receptor assay
ER assays were determined by the dextran-charcoal assay 
on fresh tumour samples at the time of surgery172. ER 
levels greater than or equal to 20 fmol/mg protein were 
designated positive.
Immunohistochemical staining
5fjm thick sections of tissue were cut and ovened at 
60°C for 30 minutes. Sections were soaked in xylene for 
10 minutes then washed in alcohol (3 changes), 
methylated spirits (2 changes) and rinsed in methanol. 
Sections were then soaked in a solution of methanol and 
0.5% hydrogen peroxide (60ml:1ml) for 30 minutes to 
block endogenous peroxide activity. Slides were then 
laid out on trays and a blocker solution of 2% bovine 
serum albumin in phosphate buffer solution was applied 
and left for 10 minutes. The blocker was then tipped 
off and the primary antibody was applied to the 
sections in dilutions as detailed above. Sections were 
incubated at 4°C for 18 hours after which they were 
washed with phosphate buffer solution for 30 minutes. 
Secondary antibody was then applied in two layers for 
45 minutes each. The secondary antibodies were biotin 
conjugated anti-mouse immunoglobulin and ExtrAvidin 
peroxidase (ExtrAvidin mouse kit, Sigma
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immunochemicals, Poole, Dorset) applied at 1:25 
dilution in 2% bovine serum albumin/phosphate buffer 
solution and pooled normal human serum (also at 1:25 
dilution). Sections were washed with phosphate buffer 
solution for 30 minutes between and after the secondary 
antibody layers were applied. Visualisation was 
achieved using 3,3’-Diaminobenzidene tetrahydrochloride 
dihydrate D.A.B (Aldrich Chemicals, Gillingham, Dorset) 
as a working solution of 1ml 0.04% DAB, 225ml 0.05M
Tris buffer (Sigma), 25ml 0.1M imidazole in 0.05M Tris 
buffer (Sigma) and 125|ul hydrogen peroxide (BDH) .
Two sections per patient were used, each taken from a 
different tissue block. For the purposes of this study 
and according to the criteria of Wright et al and other 
studies, only definite membrane staining was reported 
as c-erbB-2 positive133' 164, 165. previous studies using 
the NCL-CB11 monoclonal antibody to c-erbB-2 protein 
have defined positive staining as > 25% of cells with 
membrane staining136. No difference in prognosis was 
found comparing tumours with no staining against those 
with weak staining. In this study therefore, c-erbB-2 
staining intensity was scored as 0 for no staining or 
cytoplasmic staining or weak membrane staining (<25% of 
cells) , 1 for >25% cells with membrane staining and 2
for >50% cells with membrane staining. In keeping with 
previous studies any cells showing nuclear staining 
were reported as positive for p5 3 13^,161,164. staining
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intensity was therefore scored as 0 for no staining, 1 
for <25% cells with nuclear staining, 2 for >25% cells 
with nuclear staining and 3 for >50% cells with nuclear 
staining. The higher score for the 2 sections 
determined the overall score assigned to each patient. 
All tumours scoring 0 were termed negative.
RESULTS
The staining scores for 252 tumours stained for c-erbB- 
2 and p53 and 275 tumours stained for oestrogen 
receptor are shown in Table 24. All tumours with cells 
staining were scored as positive for c-erbB-2 and p53.
A total of 70 tumours were scored as positive for c- 
erbB-2 (27.7%), 59 were positive for p53 (23.4%) and
202 were positive for oestrogen receptor (73.5%).
Relationship between tumour bed positivity and c-erbB-2
No statistically significant relationship was found 
between tumour bed status and c-erbB-2 status (p=0.65, 
Table 25). Among patients who were tumour bed positive,
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c-erbB-2 staining was more intense among those who had 
an in-situ component in the cavity shavings.
Table 24. Results staining for c-erbB-2, p53 and 
oestrogen receptor.
SCORE C-ERBB-2 P53 OESTROGEN RECEPTOR
0 182 193 Negative 7 3
1 62 46 Positive 202
2 8 11
3 2
Relationship between tumour bed positivity and p53
No statistically significant relationship was found 
between tumour bed status and p53 status (p=0.827, 
Table 26).
Relationship between tumour bed positivity and 
oestrogen receptor
No statistically significant relationship was found 
between tumour bed status and ER status (p=0.462, Table
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27) . A trend for tumour bed positivity to be associated 
with ER positivity was observed.
Table 25. Relationship between tumour bed positivity 
and c-erbB-2 positivity.
Total C-ERBB-2 POSITIVE
CAVITY SHAVINGS
• Invasive only 24 3 (12.5)
• Invasive + In-situ 24 12 (50. 0)
• In-situ only 51 14 (27.5)
Total Positive 99 29 (29.3)
Total Negative 153 41 (26.8)
BED BIOPSIES
Positive 15 3 (26. 7)
Negative 122 33 (18. 9)
Values in parentheses are percentages.
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Table 26. Relationship between tumour bed positivity
and p53 positivity.
Total P53 POSITIVE
CAVITY SHAVINGS
• Invasive only 24 7 (2 9 .2)
• Invasive + In-situ 24 6 (2 5 . 0)
• In-situ only 51 11 (2 1 .6)
Total Positive 99 24 (2 4 .2)
Total Negative 153 35 (2 2 .9)
BED BIOPSIES
Positive 15 2 (13.3)
Negative 122 15 (12.3)
Values in parentheses are percentages.
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Table 27. Relationship between tumour bed positivity
and oestrogen receptor positivity.
Total OESTROGEN RECEPTOR 
POSITIVE
CAVITY SHAVINGS
• Invasive only 2 7 2 3 (85.2)
• Invasive + In-situ 2 5 1 8 (72. 0)
• In-situ only 5 9 4 5 (76.3)
Total Positive 1 1 1 8 6 (77.5)
Total Negative 1 6 4 1 1 6  (70.7)
BED BIOPSIES
Positive 1 6 1 4 (87.5)
Negative 1 3 1 9 9 (75. 6)
Values in parentheses are percentages.
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DISCUSSION
This study has shown no significant association between
tumour bed positivity and c-erbB-2 status, p53 status
or ER status. The incidence of positive staining for
these biological factors was consistent with previous
studies. C-erbB-2 positivity tended to be associated
with an in-situ component in the cavity shavings. C-
erbB-2 is usually found to be positive in tumours with
a large intraduct component and comedo-type DCIS128- 
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In keeping with the non-significant association between 
ER status and local recurrence reported in the 
literature, this study has found no correlation between 
ER status and tumour bed positivity.
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CHAPTER 4
INTRODUCTION
The reported incidence of local recurrence at five 
years after breast-conserving surgery and radiotherapy 
ranges from 0 . 3 %  after quadrantectomy to between 2 . 3  
and 8% after lumpectomy in randomised t r i a l s 4 3 - 4 5 ,  6 3 .  
In non-randomised series of patients local recurrence 
has been observed in as many as 21% of patients^O.
Local recurrence after breast-conserving surgery is 
associated with a short distant disease-free survival. 
Patients with local recurrence are 2 to 4 times more 
likely to develop distant disease than those without 
local recurrence and this risk increases to six-fold if 
local recurrence occurs within 1 year of s u r g e r y 4 4 , 4 7 -  
49. As detailed earlier, early local recurrence can be 
attributed to residual disease left behind at the time 
of surgery.
The evidence implicating local recurrence with the 
development of disseminated disease does not however 
translate into significant differences in survival 
between the treatment arms of randomised trials^3- 
45,49^ Currently, the generally accepted explanation of 
the relationship between local recurrence and systemic
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[recurrence is that local recurrence is a marker of poor 
prognosis rather than a cause of it^9.
The study presented in this chapter was designed to 
answer the following questions:
• What is the outcome in terms of disease recurrence 
and survival for the patients presented in Chapter 
1?
• What factors influenced prognosis?
• Is tumour bed positivity a marker of poor prognosis 
following breast-conserving surgery?
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PATIENTS AND METHODS 
Patients and follow-up
The data presented in this chapter relates to the 
patients presented in Chapter One. All patients were 
followed up at 3 monthly intervals for the first 5 
years at alternate surgical and oncology clinics, and 6 
monthly intervals thereafter. Total follow-up time was 
calculated from the date of operation to the last 
clinic visit. For patients who had failed to attend the 
clinic in the past year, their General Practitioner was 
contacted and a clinic visit was arranged. For patients 
who had died outwith hospital, the cause of death was 
obtained from death certificates.
Statistical analysis
Patients were analysed with regard to disease-free, 
distant disease-free and overall survival (see below). 
Univariate analyses were performed using Kaplan Meier 
techniques for estimation of the survival curves and 
the log rank test for comparison of different patient 
subgroups. The subgroups analysed were patient age, 
tumour grade, tumour size, lymphatic/vascular invasion, 
nodal status, c-erbB-2 status, p53 status, ER status
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and tumour bed status. For continuous measurements the 
cases were split into groupings defined by the 
quartiles of the measurements. Multivariate analysis 
was performed for distant disease-free survival using 
Cox Proportional Hazards M o d e l s - * - ^  to allow assessment 
of the inter-relationship between variables. This was 
performed in a stepwise manner. The initial model 
consisted of the variable with the greatest statistical 
significance. The significance of those variables not 
in the model was then assessed adjusting for the 
variable in the model. The most significant of these 
variables was then entered into the model and the 
significance of the remaining variables assessed. This 
was repeated until none of the variables outwith the 
model were significant after adjustment for those in 
the model.
The following end points were used :
Disease-free survival
Percentage of patients who are alive and free of loco- 
regional and distant disease at the time of follow-up.
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Distant disease-free survival
Percentage of patients who are free of distant disease 
at the time of follow-up.
Overall survival
Percentage of patients who have not died as a result of 
breast cancer at the time of follow-up.
RESULTS
Two patients were lost to follow-up and 298 patients 
were therefore evaluable. Mean follow-up was 4.4 years 
(range 2.0 to 7.5 years).
All patients received post-operative radiotherapy to 
the breast, 232 patients received tamoxifen and 18 
patients received chemotherapy. The administration of 
adjuvant tamoxifen and chemotherapy did not differ 
significantly relative to tumour bed status (p=0.62 and 
p=0.59 respectively, Chi-square test). This is shown in 
Table 28.
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Table 28. Number of patients who received adjuvant 
treatment relative to tumour bed positivity.
ADJUVANT ALL PATIENTS TUMOUR BED TUMOUR BED
TREATMENT NEGATIVE POSITIVE
Tamoxifen 232 (76.7) 139 (76.4) 93 (78.8)
Chemo therapy 18 (6.0) 12 (6.6) 6 (5.1)
Values in parentheses are percentages.
Site of recurrence
The site of first relapse is shown in Table 29. A total 
of 24 patients died from breast cancer and 11 died from 
other causes. Seven patients were alive with distant 
recurrence at the time of follow-up. One patient with 
local recurrence as the first site of disease relapse 
was alive with distant disease. Four patients developed 
a second primary tumour in the contralateral breast.
Of 267 patients who were treated by breast-conserving 
surgery (excluding 33 patients treated by mastectomy 
for extensive tumour bed disease) , 24 patients
developed distant disease of which 19 died. Nine
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patients died of other causes and 3 developed a second 
primary tumour in the contralateral breast.
Table 29. Frequency of first site of disease 
recurrence.
TYPE OF RECURRENCE ALL PATIENTS PATIENTS TREATED BY 
BREAST-CONSERVING 
SURGERY ONLY
Local 6 (2.0) 6 (2.3)
Axillary 2 (0.7) 2 (0.7)
Systemic 31 (10.4) 24 (9.0)
Values in parentheses are percentages.
There were 6 local recurrences. The clinico- 
pathological characteristics for these patients are 
shown in Table 30. The mean age of patients with local 
recurrence was 41.4 years. Only 2 patients with local 
recurrence had a positive tumour bed. Both had less 
than 4 foci of disease in the cavity shavings and did 
not receive further surgery for tumour bed positivity.
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Local recurrence was detected by clinical examination 
in 5 patients and by mammography in the remaining 
patient. All affected the site of previous excision. 
The recurrence was invasive in 5 patients and in-situ 
in 1 patient. All invasive recurrences except one had 
the same Bloom and Richardson grade as the original 
tumour. For one patient the recurrence was grade 3 and 
the primary tumour, grade 2. Treatment of local 
recurrence was by mastectomy in 5 patients and wide 
excision in 1 patient.
Two patients with local recurrence (A and C) were ER 
negative, no patient was c-erbB-2 positive and 1 
patient was p53 positive (F).
All patients were re-staged by bone scan, liver 
ultrasound and chest x-ray at the time of local 
recurrence. In all cases these investigations were 
negative. One patient (patient B in Table 30) 
subsequently developed distant metastases four and a 
half years after local recurrence.
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Table 30. Patients with local recurrence.
PATIENT
A B C D E F
Age 66 43 28 34 37 39
Cavity shaving Neg Neg Neg Neg Inv In-situ
Bed biopsies Neg Neg
Tumour size(mm) 20 20 15 10 20 12
Tumour grade 3 2 2 1 2 2
Intraduct
component
None None None Ext None None
Lymphatic/
vascular
No No No Yes No No
invasion
Axillary lymph 
node status
Neg Pos Pos Pos Neg Neg
Chemotherapy No Yes Yes Yes No No
Tamoxifen Yes No No No No No
Site of 
recurrence
All at site of previous operation
Size of
recurrence (mm)
20 Diffuse 16 In-situ 17 10
Neg = negative, Pos = positive, Inv = invasive, Ext = 
extensive
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Univariate analysis of disease-free survival
Results are shown in Table 31. Useful predictors of 
disease-free survival were nodal status,
lymphatic/vascular invasion, ER status, tumour grade 
and tumour bed status.
Univariate analysis of distant disease-free survival
Results are shown in Table 32. All variables apart from 
c-erbB-2 and p53 had significant or near-significant 
associations with distant recurrence. The relative 
hazards for the predictors of distant disease-free 
survival are shown in Table 33. Patients who were 
tumour bed positive were twice as likely to suffer 
distant disease recurrence than patients who were 
tumour bed negative. The life-table analysis of tumour 
bed status in relation to distant disease is shown in 
Illustration 5. Distant disease-free survival was not 
significantly related to the type of disease found in 
the tumour bed (Illustration 6).
Univariate analysis of overall survival
Results are shown in table 34. The only variables 
useful in predicting overall survival were tumour bed 
status and age at operation.
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Table 31. Univariate analysis of disease-free survival.
VARIABLE LOG RANK TEST
Age p = 0.377
Tumour Grade p = 0.039*
Tumour Size p = 0.115
Nodal Status p = 0.003*
Oestrogen Receptor Status p = 0.012*
Lymphatic/Vascular Invasion p = 0.006*
C-erbB-2 status p = 0.364
p53 status p = 0.372
Tumour Bed Status p = 0.042*
* Statistically significant
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Table 32. Univariate analysis of distant disease-free
survival.
VARIABLE LOG RANK TEST
Age p = 0.035*
Tumour Grade p = 0.019*
Tumour Size p = 0.068
Nodal Status p = 0.007*
Oestrogen Receptor Status p = 0.020*
Lymphatic/Vascular Invasion p = 0.002*
C-erbB-2 Status p = 0.304
p53 Status p = 0.335
Tumour Bed Status p = 0.042*
* Statistically significant
Table 33. Relative hazards for variables associated 
with distant disease-free survival (Univariate 
analysis).
VARIABLE COMPARISON FOR 
RELATIVE HAZARD 
ESTIMATION
RELATIVE HAZARD *
Age UQ vs LQ 0.86 (0.57 to 1.31)
Tumour Grade 2 vs 1 3.30 (0.95 to 11.5)
3 vs 1 5.50 (1.45 to 20.9)
3 vs 2 1.66 (0.73 to 3.76)
Tumour Size UQ vs LQ 1.66 (1.08 to 2.54)
Nodal Status Pos vs Neg 2.70 (1.25 to 5.83)
Oestrogen Receptor Neg vs Pos 2.26 (1.10 to 4 . 66)
Status
Lymphatic/Vascular Present vs 2.94 (1.44 to 6.01)
Invasion Absent
Tumour Bed Status Pos vs Neg 2.03 (1.00 to 4.15)
* Point estimate for relative hazard (95% confidence 
intervals for relative hazard in parenthesis).
UQ = Upper Quartile, LQ = Lower Quartile.
Pos = positive, Neg = negative
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Illustration 5. Life table analysis of tumour bed
status and distant disease-free survival
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Illustration 6. Life table analysis of type of disease
in tumour bed and distant disease-free survival
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Table 34. Univariate analysis of overall survival.
VARIABLE LOG RANK TEST
Age p = 0.049*
Tumour Grade p = 0.329
Tumour Size p = 0.306
Nodal Status p = 0.167
Oestrogen Receptor Status p = 0.143
Lymphatic/Vascular Invasion p = 0.638
C-erbB-2 Status p = 0.255
p53 Status p = 0.590
Tumour Bed Status p = 0.016*
* Statistically significant
Multivariate analysis of distant disease-free survival
Three variables were identified as a set of 
independently useful predictors of distant disease-free 
survival; Lymphatic/Vascular invasion, ER status and 
Tumour Bed status. These factors constituted the final 
Cox proportional hazards model. After adjusting for 
these factors, none of the other variables were useful 
in predicting distant disease-free survival. No 
statistically significant interaction was found between 
tumour bed positivity and lymphatic/vascular invasion
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(p=0.783, likelihood ratio test) or tumour bed 
positivity and ER status (p=0.665, likelihood ratio 
test) . Life table analyses of tumour bed status and 
lymphatic/vascular invasion or tumour bed status and ER 
status are shown in Illustrations 7 and 8. Patients 
with ER negative and tumour bed positive tumours 
appeared to be at particular risk of distant disease 
with a distant disease-free survival of 49.6%.
Distant disease-free survival relative to further 
surgery performed for tumour bed positivity
To assess the influence of performing further surgery 
on the outcome of patients who were tumour bed positive 
a life table analysis was performed for distant 
disease-free survival. There was no significant 
difference in outcome between those who were tumour bed 
positive and had further surgery and those who were 
tumour bed positive and had no further surgery (p=0.09, 
Illustration 9). However those patients who had further 
surgery tended to be more likely to develop distant 
disease than those who had no further surgery, 
regardless of tumour bed status.
The 33 patients who had mastectomy were compared with 
the 277 patients treated by breast-conserving surgery 
(plus or minus re-excision). The relative distribution
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of tumours in terms of size, grade and lymph node 
status between these two groups is shown in Table 35. 
Patients who had mastectomy were more likely to be node 
positive (p=0.029, chi-square) and tended to have 
higher grade tumours (p=0.053, chi-square). Distant 
disease-free survival for mastectomy patients was 78.8% 
versus 91.0% for patients treated by breast-conserving 
surgery (median 4.5 years for both groups, p=0.037 Log 
Rank test, Illustration 10) .
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Table 35. Distribution of tumour size, grade and lymph 
node status between patients treated by mastectomy and 
those treated by breast-conserving surgery.
MASTECTOMY BREAST-CONSERVING
SURGERY
Median tumour 
diameter (mm)
12 13
Tumour grade
• I 2 (6.1) 70 (25 .3)
• II 22 (66. 7) 123 (44.4)
• III 5 (15.2) 36 (13. 0)
• ungraded 4 (12.1) 38 (13. 7)
Lymph node
• Negative 21 (66. 7) 222 (80.1)
• Positive 12 (33.3) 55 (19.9)
Values in parentheses are percentages.
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Illustration 7. Life table analysis of tumour bed
status and lymphatic/vascular invasion and distant
disease-free survival
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Illustration 8. Life table analysis of tumour bed
status and ER status and distant disease-free survival
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Illustration 9. Life table analysis of further surgery
and distant disease-free survival
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Illustration 10. Life table analysis comparing
patients treated by mastectomy with those treated by 
breast-conserving surgery (distant disease-free 
survival)
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DISCUSSION
A low local recurrence rate of 2% has been observed in 
this study. This is comparable with the lowest reported 
rates of local recurrence in the literature (Table 4) . 
All patients in this study received post-operative 
radiotherapy, 77% received adjuvant tamoxifen and 6% 
received adjuvant chemotherapy. With short-term follow- 
up and few local recurrences analysis of factors 
associated with local recurrence is premature. However, 
a significant feature of the 6 patients with local 
recurrence was that their mean age was 41.4 years and 
only 1 patient was over 43 years old. The association 
between young age and local recurrence is well 
recognised. Several investigators have shown that risk 
of local recurrence decreases with advancing age and 
that patients aged below 40 years are at the highest 
risk^3'47,83,90,176,177. jn a regression analysis of 
patients treated with lumpectomy and radiotherapy in 
the NSABP-B06 trial, age less than 35 years was the 
most significant prognostic factor for local 
recurrence^. In Chapter 1 no statistically significant 
association was found between age and tumour bed 
positivity although the incidence of tumour bed 
positivity varied with age and patients between 35 and 
50 were more likely to be tumour bed positive. All
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local recurrences in this study affected the site of 
previous excision and hence are likely to represent 
residual disease. However, only two patients with local 
recurrence had evidence of residual disease in the 
cavity shavings and this was very minimal involvement. 
The rest were tumour bed negative and 2 had negative 
bed biopsies. Other factors other than residual tumour 
burden might therefore have an important role in the 
aetiology of local recurrence in young women. Young age 
has been reported to be associated with an increased 
risk of local recurrence regardless of whether or not 
radiotherapy was administered^-1^ . Resistance to 
radiotherapy therefore, does not appear to be a concern 
nor does it explain the association. Young patients 
with breast cancer are known to have more aggressive 
tumours with a worse overall outcome regardless of 
surgical treatment. It has been suggested that the 
reason for the increased risk of local recurrence in 
young women is related to high circulating oestrogen 
levels178. It has also been suggested that the chemical 
environment at the operation site in young women may be 
very conducive to the culture of very small numbers of 
residual tumour cells17 .^
Follow-up for this study was relatively short and given 
that all tumours were less than 25mm it is not 
surprising that overall survival was good. Longer 
follow-up will allow a more powerful analysis of
149
variables predicting outcome. However distant disease- 
free survival is a surrogate measure of overall 
survival when follow-up is limited. As 5 patients in 
this study were alive with distant disease it was 
important to assess variables for a significant 
relationship with this outcome measure as well as for 
overall survival. Not surprisingly, some variables were 
found to significantly predict for distant disease-free 
survival but not overall survival.
In this study, tumour bed positivity was associated 
with a short distant disease-free survival. Patients 
with disease in the tumour bed were twice as likely to 
develop distant metastasis compared with patients who 
were tumour bed negative. In addition, multivariate 
analysis showed that lymphatic/vascular invasion, ER 
status and tumour bed status were all independently 
useful predictors of distant disease-free survival. 
After adjusting for these factors no other variables 
were significant. This included tumour grade which was 
the only factor significantly associated with tumour 
bed positivity in Univariate analysis. The type of 
disease (in-situ or invasive) found in the tumour bed 
was also not significantly associated with distant 
disease-free survival. Failure to find a significant 
relationship between c-erbB-2 and survival in this 
series may be due to the relatively small numbers of 
node positive patients, a group in whom the prognostic
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power of c-erbB-2 is most likely to be apparent. 
Patients who were ER negative and tumour bed positive 
appeared to have a particularly high risk of distant 
metastasis with a distant disease-free survival of less 
than 50% compared to greater than 90% for patients who 
were ER positive and tumour bed negative.
In reviewing the literature for previous reports of an 
association between tumour bed disease and patient 
outcome, the study by Egan et al is of interest^. This 
study analysed 118 mastectomy specimens containing 
invasive primary cancers and documented the presence of 
multifocal disease using a detailed pathological- 
radiological technique. The findings were correlated 
with patient survival. Patients with unifocal disease 
had a significantly better prognosis than those with 
multifocal tumours regardless of tumour stage.
An association . between local recurrence and distant 
disease is well recognised as detailed earlier. 
Currently, the generally accepted theory to explain 
this association is that local recurrence is merely a 
visible manifestation of the original tumour and is 
thus a marker for distant disease rather than a direct 
cause of it. Residual disease after breast-conserving 
surgery is the cause of early local recurrence and 
hence tumour bed positivity might be expected to also 
correlate with, prognosis as has been demonstrated.
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Therefore, the mechanism for the association between 
tumour bed positivity and distant disease may be the 
same as that between local recurrence and distant 
disease.
In the NSABP-B06 trial 10% of patients had a positive 
resection margin determined by India ink staining and 
these patients all underwent mastectomy^. 
significant difference in survival was found between 
patients receiving 'breast-conserving surgery alone and 
those who also received adjuvant radiotherapy despite 
large differences in local recurrence rates^. jn this 
study 41 patients (14%) underwent further surgery 
determined by extensive disease involvement of the 
cavity shavings. The distant disease-free survival 
tended to be worse for those patients who had further 
surgery compared to those who did not. This finding is 
consistent with the view that no causal relationship 
exists between residual disease in the tumour bed and 
distant disease-free survival.
Patients who underwent mastectomy were also analysed 
separately and compared with those who were treated by 
breast-conserving surgery. There was a 12% difference 
in distant disease-free survival with mastectomy 
patients having a worse prognosis. When pathological 
features were compared between these two groups, this 
difference in prognosis could be explained by the fact
152
that mastectomy patients had tumours with higher grade 
and a higher incidence of lymph node positivity. In 
addition, of course, they all had positive cavity 
shavings.
Taken together, these results favour the hypothesis put 
forward by Fisher that prognosis is determined by 
tumour biology and not influenced by local 
recurrence^.
In conclusion, tumour bed analysis is a useful method 
of assessing completeness of surgical excision. A 
selective re-excision policy for cavity shaving 
positivity results in a low local recurrence rate. This 
study has also demonstrated that tumour bed status is 
an independent marker for distant disease-free 
survival.
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FINAL DISCUSSION
In the treatment of patients with breast cancer, the 
role of surgery is to achieve local control of disease 
and allow pathological tumour staging. During this 
century the surgical strategy to achieve these aims has 
evolved from radical mutilating dissections of the 
chest wall to increasingly conservative procedures. 
Most recently the use of breast-conserving surgery has 
become widespread. Breast-conserving operations are 
designed to achieve the same degree of disease control 
as more radical procedures but with considerably better 
cosmesis and considerably less psychological morbidity. 
Several randomised trials have assessed the value and 
safety of breast-conserving surgery. It has become 
clear that breast-conserving surgery combined with 
axillary dissection and post-operative radiotherapy to 
the residual breast tissue is a safe alternative to 
radical mastectomy for treating small breast cancers. 
Five year local recurrence rates after this treatment 
regime are 2.3 to 8% (table 4) and may be lower if 
chemotherapy is also given. Breast-conserving surgery 
alone, without radiotherapy, results in an unacceptably 
high incidence of local recurrence. Currently 
therefore, radiotherapy is a mandatory adjunct to 
breast-conserving surgery. However it also has an
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associated morbidity and for many patients it is a
significant ordeal and inconvenience.
The large majority of local recurrence after breast- 
conserving surgery alone (without radiotherapy) occurs 
within the first 5 years of surgery at the site where 
the primary tumour was excised. This would appear to 
indicate that the initial surgical procedure may have 
been incomplete. This scenario has been previously 
demonstrated by pathological studies, which showed that 
microscopic disease frequently extends beyond the 
macroscopic boundary of the tumour (multifocality) . In 
over 40% of cases multifocality was observed to extend 
beyond what might be considered an adequate "gross" 
excision margin by the surgeon.
Currently approximately half of all new cases of breast 
cancer are treated by breast-conserving surgery. Both 
breast cancer screening and the use of neoadjuvant 
chemoendocrine therapy are likely to increase the 
proportion of tumours suitable for breast-conserving 
procedures in the future. Measures taken to prevent 
local recurrence are important for several reasons; 
local recurrence is difficult to detect, is likely to 
require mastectomy and in many cases may be inoperable. 
It is also likely to be associated with extreme patient 
anxiety. In addition there is indirect evidence 
supporting the controversial theory that local
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recurrence may disseminate and directly effect overall 
outcome for some patients. Finally, if patients at risk 
of local recurrence can be identified, then 
radiotherapy could be administered selectively.
Pathological and clinical risk factors for local 
recurrence have been investigated extensively. 
Withholding adjuvant radiotherapy is undoubtedly the 
most important predictor of increased risk for local 
recurrence. Another important predictor is margin 
status. Microscopic disease at resection margins is a 
strong indicator of risk for early local recurrence. 
Other major risk factors are young age and the presence 
of an extensive in-situ component in the tumour. Less 
consistent associations are found between local 
recurrence and high tumour grade, lymphatic/vascular 
invasion and tumour size.
This thesis has presented a novel and simple method for 
analysing the resection margin. This involves taking a 
shaving from the wall of the cavity remaining in the 
breast after the surgeon has performed what he regards 
as an adequate wide local excision (Chapter 1) . This 
method avoids the difficulties encountered during 
assessment and interpretation of margin analyses based 
on sections taken from the lumpectomy specimen surface. 
In a series of 300 patients, microscopic disease was 
detected within the cavity shaving in 39.3% (tumour bed
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positivity). This incidence of margin positivity is 
considerably higher than those reported by other 
studies using conventional methods of margin analysis. 
However it is consistent with predictions of tumour bed 
positivity based on pathological studies and is 
consistent with the reported incidence of local 
recurrence after breast-conserving surgery if adjuvant 
radiotherapy is withheld (43%, table 4).
The extent of tumour bed positivity varied widely. In 
many instances only 1 or 2 foci of in-situ cancer were 
detected in 1 or 2 sections out of 30 blocks sectioned. 
In other cases extensive invasive disease involving 
many blocks was found. Tumour bed positivity consisted 
of invasive disease in 18.3% of patients and only a 
third of patients had more than 4 foci of residual 
disease. All patients received adjuvant radiotherapy. 
It is not known how much residual disease can be safely 
treated by radiotherapy. With a selective re-excision 
policy targeted at patients with evidence of extensive 
tumour bed positivity, further disease was found in 22 
out of 41 patients who had further wider excision or 
mastectomy. At mean follow-up of 4.4 years this policy 
resulted in a local recurrence rate of 2% (Chapter 4). 
This rate compares very favourably with 5-year local 
recurrence rates reported in the literature.
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These advantages of cavity shaving must be weighed 
against the preparation and reporting time for this 
technique. It might be argued that a cost benefit
analysis comparing standard methods of margin 
assessment with cavity shaving would be likely to show 
no difference or even favour cavity shaving. With 
standard methods, preparation time may be longer as the 
specimen requires more detailed and accurate 
preparation and microscopy requires an excision margin 
to be identified and measurements to be taken. In 
addition, the fact that cavity shaving can quantify
residual disease and that patients with minimum 
residual disease do not undergo re-operation must be 
compared with standard methods which cannot quantify
residual disease and are thus unable to select patients 
who do not require re-excision. If long-term follow up 
supports cavity shaving as a technique resulting in a 
low rate of local recurrence as this study suggests, 
then this will also represent a cost benefit.
Factors that might predict risk of tumour bed
positivity were assessed. Such factors might alter 
surgical policy if detected at diagnostic biopsy or 
pre-operatively by mammography. Thus certain patients 
might be selected for a wider initial resection. Tumour 
bed positivity was found to be significantly associated 
with higher tumour grade, presence of a large in-situ 
component, dense mammographic pattern, casting-type
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mammographic calcification and absence of mammographic 
nidus. Non-significant trends were also observed
between tumour bed positivity and smaller lumpectomy 
diameter, younger patient age and lobular carcinoma. Of 
interest, no association was found between tumour bed 
positivity and tumour size, lymphatic/vascular 
invasion, axillary lymph node metastases, and oestrogen 
receptor, c-erbB-2 and p53 status (Chapters 1,2 and 3).
Of the 300 patients who had tumour bed analysis, 165 
had bed biopsies taken from the cavity wall remaining 
after the cavity shaving had been taken. For the 41 
patients who had re-excision because of extensive
tumour bed positivity, the likelihood of finding
further disease was associated with disease in the bed 
biopsies, 4 or more foci of disease in the cavity
shavings and a large intraduct component in the tumour
(Chapter 1).
On the basis of these results, a future study might 
prospectively investigate the value of these criteria 
to select patients for wider primary excision.
Similarly, patients who are tumour bed negative with no 
intraduct component may not require radiotherapy. A 
randomised trial of selected patients might assess
this. Interestingly, a study similar to this has
recently been r e p o r t e d ^ O . Radiotherapy was not given 
to patients with unicentric, clinically T1 tumours that
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had no extensive intraduct component or lymphatic 
vessel invasion and had a negative pathological 
clearance margin of at least 1cm (determined by 
inking). After a median follow-up of 4.7 years the 
local recurrence rate was 16% and the trial was 
prematurely closed. This study did not state the number 
of patients who might have been suitable for enrolment 
but were excluded because of positive margins. As 
previously stated, inking is known to underestimate 
margin positivity and 79% of local recurrence in this 
study affected the site of original excision. Thus, 
original assessment of margins may have been 
inadequate. The need for caution in assessing the role 
for performing breast-conserving surgery without 
radiotherapy is highlighted. However, even if highly 
selective criteria are used (including perhaps patient 
age and tumour grade) a significant percentage of 
patients may avoid radiotherapy. Another study 
addressing this issue is the BASO II trial (British 
Association of Surgical Oncology). This trial was 
started in 1991 and is currently in progress. Patients 
who have grade I or special type tumours, 2cm or less 
in diameter and are axillary node negative are eligible 
for enrolment. They are randomised to wide local 
excision plus or minus radiotherapy181. The trial did 
not specify a particular technique for margin analysis, 
stating only that clear margins should be confirmed by
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microscopy. The results of this trial may also, 
therefore, highlight the necessity of adequate and 
detailed margin assessment. Analysis of the factors 
which are associated with tumour bed positivity in a 
larger number of patients than that presented in this 
thesis may shed further light on the criteria which 
would be most useful in selecting patients for whom 
radiotherapy can be safely omitted.
Tumour bed positivity was also assessed as a prognostic 
factor for distant disease-free survival. This was of 
interest because of the strong association reported 
between local recurrence and distant disease-free 
survival. Patients who were tumour bed positive were 
found to be significantly more likely to develop 
distant disease than patients who were tumour bed 
negative within the limited follow-up period of this 
study (Chapter 4) . This relationship requires further 
investigation. Specifically, with larger numbers of 
patients or longer follow-up it may be possible to show 
that the strength of this association is related to the 
extent of tumour bed positivity. Patients who had 
further surgery because of extensive tumour bed disease 
tended to have a shorter distant disease-free survival 
than those who were tumour bed positive but had no 
further surgery.
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In summary, investigations into the causes and methods 
of preventing local recurrence after breast-conserving 
surgery is of great interest and is relevant to the 
current surgical management of patients with breast 
cancer. Hopefully our understanding of local recurrence 
has progressed a little with the investigations 
performed in this thesis.
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